Molecules and their methods of use

Abstract

The present invention provides novel molecules, compositions containing such molecules, and methods for using such molecules for the treatment of various conditions.

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Patent Application No. 63 / 498,511, filed on 26 April 2023, the contents of which said Provisional Patent Application are incorporated herein by reference in their entirety.

[0002] Sequence List This application includes a sequence listing submitted electronically in XML format, the entirety of which is incorporated herein by reference. The XML copy, created on 19 April 2024, is named Woolwich_001_WO1_SL and is 2,453,732 bytes in size.

[0003] Embedding by reference In jurisdictions that permit incorporation by reference, the contents of all documents referenced herein are incorporated herein in their entirety by reference. [Background technology]

[0004] Opioid receptors are seven-transmembrane G protein-coupled receptors. There are four types of opioid receptors: the mu receptor, delta receptor, kappa receptor, and nociceptin receptor. Endogenous opioids and opioid drugs can activate these opioid receptors, potentially producing analgesic and other biological effects. Research suggests that delta opioid receptor agonists may play a role in a variety of therapeutic areas, including but not limited to the management of chronic and acute pain. 1~25 However, while several delta-opioid agonists have been identified, none have yet been approved by regulatory bodies for the treatment of pain or other conditions. There is a need for novel delta-opioid receptor agonists in this technology field for at least the following reasons: Firstly, there is a need for chemically novel delta-opioid agonists to promote a mechanistic understanding of the role of delta-opioid receptors in human pathophysiology. Secondly, there is a need for a new, chemically novel delta-opioid agonist that is safe and avoids some of the adverse events (such as seizures) observed with previous delta-opioid agonists. ●Thirdly, there is a need for chemically novel molecules, including chemically novel delta-opioid agonists, that demonstrate clinical analgesic efficacy. Fourthly, there is a need for chemically novel molecules, including chemically novel delta-opioid agonists, that have a sufficiently long duration of action to be clinically useful (for example, for the treatment of pain). Fifth, there is a need for chemically novel molecules, including chemically novel delta-opioid agonists, that are effective when delivered orally (for example, for the treatment of pain). Sixth, there is a need for chemically novel molecules, including chemically novel delta-opioid agonists, that demonstrate analgesic efficacy in various animal species, including non-human primates. ●Seventh, there is a need for chemically novel molecules, including chemically novel delta-opioid agonists, that demonstrate analgesic efficacy in various animal models, such as acute mechanical pain, acute thermal pain, inflammatory pain, visceral pain, and / or neuropathic pain. ●Eighth, there is a need for chemically novel analgesic molecules, including chemically novel delta-opioid agonists, that have a site of action other than the central nervous system. ●Ninthly, there is a need for chemically novel analgesic molecules, including chemically novel delta-opioid agonists, that do not exhibit undesirable neurological effects such as anesthetic effects. ●Tenthly, there is a need for chemically novel analgesic molecules, including chemically novel delta-opioid agonists, that do not induce tolerance with repeated administration and can maintain clinical efficacy with repeated administration. ● Eleventhly, there is a need for chemically novel delta-opioid agonists that have analgesic efficacy primarily mediated by delta-opioid receptors and not mu-opioid receptors (as demonstrated, for example, by the use of antagonist and / or gene knockout models). ●Twelfth, there is a need for a new, chemically novel delta-opioid agonist that is stable for long periods as a solid and / or in solution at room temperature and / or high temperatures. ●Thirteenth, there is a need for a new, chemically novel delta-opioid agonist that is stable in acidic and / or peroxide solutions, and / or under ultraviolet light. ●Fourteenth, there is a need for a biased DOR agonist, a chemically novel delta opioid agonist that has higher potency (lower EC50) and / or activity (higher maximal effect) for one downstream effect of DOR agonism (such as cAMP production or calcium flux) than for others (such as beta-arrestin recruitment or receptor internalization). [Overview of the Initiative] [Problems that the invention aims to solve]

[0005] This invention aims to address these needs. [Means for solving the problem]

[0006] The present invention is based in part on a series of important developments and discoveries relating to delta-opioid receptor agonists, further details of which are provided in the “Examples” and “Modes for Carrying Out the Invention” sections of this patent disclosure. In summary, a panel of novel peptides has been developed that have delta-opioid receptor agonist activity, are chemically novel, do not cause convulsions in animals, exhibit analgesic efficacy in animal models, maintain analgesic efficacy over a clinically useful period in animal models, and / or are effective in exhibiting analgesic efficacy when administered orally. Based on these developments, the present invention provides a variety of novel peptide agonists of the delta-opioid receptor, compositions comprising such peptides, and methods of using such peptides.

[0007] Some of the peptides of the present invention are identified herein using sequence identification numbers (SEQ ID NOs) and / or peptide numbers (PEP numbers). Peptides that meet the requirements for inclusion in a sequence listing are assigned both the same PEP number and SEQ ID NOs. Peptides having amino acid sequences that do not meet the requirements for inclusion in a sequence listing (i.e., peptides having fewer than four defined amino acids) are assigned only the PEP number. The phrases “SEQ ID NOs and / or PEP numbers” (or plural “SEQ ID NOs and / or PEP numbers”) and “PEP numbers and / or SEQ ID NOs” (or plural “PEP numbers and / or SEQ ID NOs”) may be used to refer to peptides or groups of peptides, some of which may include SEQ ID NOs. For peptides with an SEQ ID NO: this phrase should be understood to refer to the SEQ ID NO of that peptide, and for peptides without an SEQ ID NO (and only with a PEP number), this phrase should be understood to refer to the PEP number of that peptide. Placeholders are inserted into the sequence listing to ensure that all peptides with both an SEQ ID NO and a PEP number have the same numbers assigned to both the SEQ ID NO and the PEP number. For further clarity, PEP numbers 199, 207, 636, 644, 756, 762, 766, 769, 771, 773, 782, 797, 811, 854, 860, 865, 869, 872, 874, 875, as well as 316 and 318-437 do not meet the sequence listing criteria, and if the SEQ ID NO appears to refer to one of these numbers, the PEP number with the same number should be considered instead. All other PEP numbers and / or sequence numbers may be referred to by any of those PEP numbers and / or sequence numbers and are included in the sequence listing.

[0008] Accordingly, in some embodiments, the present invention provides peptides comprising PEP numbers and / or amino acid sequences from SEQ ID NOs. 1 to 315. Each of these peptides has been demonstrated to exhibit activity as a delta-opioid receptor agonist in vitro.

[0009] Interestingly, PEP numbers and / or SEQ ID NOs. 305-315 are retroinverso variants of the reference alignment provided by PEP numbers and / or SEQ ID NOs. 1-304, and since each of PEP numbers and / or SEQ ID NOs. 305-315 exhibits delta-opioid receptor agonist activity, it was discovered that the retroinverso variants of our delta-opioid agonist peptide also exhibit delta-opioid receptor agonist activity in vitro. Therefore, in some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs. 438-752, which are retroinverso forms of PEP numbers and / or SEQ ID NOs. 1-315.

[0010] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs: 16, 17, 24, 86, 87, 157, 162, 163, 164, 165, 166, 167, 170, 171, 173, 175, 177, 178, 179, 182, 183, 185, 186, or 187. This group of 24 peptides was studied in an animal model of analgesia, and all 24 peptides were found to exhibit analgesic efficacy in vivo (none of the peptides tested in vivo had analgesic effect), providing evidence that the in vitro delta-opioid receptor agonist activity of the peptides of the present invention correlates with their in vivo analgesic activity. Furthermore, and importantly, the 24 peptides tested differed substantially from one another in their structure, size, length, and sequence, confirming that the ability to induce in vivo analgesia is not unique to one peptide or one narrow group of peptides, but rather appears to be a general characteristic of the invented peptides.

[0011] The analysis of the amino acid sequences of the peptides described above revealed certain common sequence motifs that can be described using consensus amino sequences. Accordingly, in some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs. 316 to 437, wherein each consensus sequence has at least one variable amino acid position. Similarly, in some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs. 747 to 875, wherein each consensus sequence represents a sequence motif shared by a number of peptides described herein.

[0012] The present invention also provides variants of the above-mentioned peptides. For example, in some embodiments, the present invention provides peptides comprising an amino acid sequence that is at least 90% identical to any one of PEP numbers and / or SEQ ID NOs. 1-315, 438-752, or 747-875, provided that the variant peptide has delta opioid agonist activity. A number of other types of variant peptides are also provided by the present invention, as described in other sections of this disclosure.

[0013] The present invention also provides compositions comprising the peptides described herein. For example, in some embodiments, the present invention provides a pharmaceutical composition comprising the peptides described herein and at least one pharmaceutically acceptable carrier or excipient.

[0014] The present invention also provides various methods for using the peptides of the present invention. For example, in some embodiments, the present invention provides a method for activating a delta opioid receptor, comprising contacting a delta opioid receptor, or a cell containing a delta opioid receptor, with the peptides described herein, in vitro or in vivo.

[0015] Similarly, in some embodiments, the present invention provides a method for treating pain in a subject requiring treatment, comprising administering an effective amount of the peptide described herein to such subject.

[0016] To facilitate the reading of this specification, the following summary table of PEP numbers and / or sequence numbers is provided. [Table 1]

[0017] These and other embodiments of the present invention are described further below. [Brief explanation of the drawing]

[0018] [Figure 1A] The amino acid sequences (PEP numbers and / or SEQ ID NOs. 1-304) of 304 delta-opioid receptor agonist peptides shown in Table 3 are aligned according to identity and numbered according to their aligned positions. Positions are numbered 1-20 (X1-X20). Each position may contain one or more amino acids, as well as other molecular elements. [Figure 1B] The amino acid sequences (PEP numbers and / or SEQ ID NOs. 1-304) of 304 delta-opioid receptor agonist peptides shown in Table 3 are aligned according to identity and numbered according to their aligned positions. Positions are numbered 1-20 (X1-X20). Each position may contain one or more amino acids, as well as other molecular elements. [Figure 1C] The amino acid sequences (PEP numbers and / or SEQ ID NOs. 1-304) of 304 delta-opioid receptor agonist peptides shown in Table 3 are aligned according to identity and numbered according to their aligned positions. Positions are numbered 1-20 (X1-X20). Each position may contain one or more amino acids, as well as other molecular elements. [Figure 1D]The amino acid sequences (PEP numbers and / or SEQ ID NOs. 1-304) of 304 delta-opioid receptor agonist peptides shown in Table 3 are aligned according to identity and numbered according to their aligned positions. Positions are numbered 1-20 (X1-X20). Each position may contain one or more amino acids, as well as other molecular elements. [Figure 1E] The amino acid sequences (PEP numbers and / or SEQ ID NOs. 1-304) of 304 delta-opioid receptor agonist peptides shown in Table 3 are aligned according to identity and numbered according to their aligned positions. Positions are numbered 1-20 (X1-X20). Each position may contain one or more amino acids, as well as other molecular elements. [Figure 1F] The amino acid sequences (PEP numbers and / or SEQ ID NOs. 1-304) of 304 delta-opioid receptor agonist peptides shown in Table 3 are aligned according to identity and numbered according to their aligned positions. Positions are numbered 1-20 (X1-X20). Each position may contain one or more amino acids, as well as other molecular elements. [Figure 1G] The amino acid sequences (PEP numbers and / or SEQ ID NOs. 305-315) of 11 delta-opioid receptor agonist peptides shown in Table 3, aligned according to identity and numbered according to the aligned position. The positions are numbered 20-1 (X20-X1) to demonstrate positional alignment with the reference alignments of PEP numbers and / or SEQ ID NOs. 1-304, of which the reference alignments of PEP numbers and / or SEQ ID NOs. 305-315 are retroinverso. The positions may contain one or more amino acids, as well as other molecular elements. [Figure 2A] In vitro agonist response curves of a peptide having PEP number and / or the amino acid sequence of SEQ ID NO: 157 in a fluorescence cAMP assay, as described in detail in Example 1. [Figure 2B]In vitro agonist response curves of a peptide having PEP number and / or the amino acid sequence of SEQ ID NO: 24 in a calcium flux assay, as described in detail in Example 2. [Figure 2C] In vitro binding curves of a peptide having the PEP number and / or the amino acid sequence of SEQ ID NO: 157 in a competitive radioligand assay, as described in detail in Example 3. [Figure 3] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence DSYGEVGVRQAPFPLSISCN (PEP number and / or SEQ ID NO: 1). [Figure 4] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence DSYGEVGVRQAPFPSRASCN (PEP number and / or SEQ ID NO: 2). [Figure 5] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence DSYGEVGVRQAPFPSRASC (PEP number and / or SEQ ID NO: 3). [Figure 6] This is an example of a predicted or modeled chemical structure of a peptide having the amino acid sequence RGDGEVGVRQAPFPLSISCN (PEP number and / or SEQ ID NO: 4). [Figure 7] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence RGDGEVGVRQAPFPLSISC (PEP number and / or SEQ ID NO: 5). [Figure 8] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence RGDGEVGVRQAPFPSRASC (PEP number and / or SEQ ID NO: 6). [Figure 9] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence RGDGEVGVRQAPYPSRASC (PEP number and / or SEQ ID NO: 7). [Figure 10] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence RGDGEVGVRQAPYLSRAFC (PEP number and / or SEQ ID NO: 8). [Figure 11] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of DGDGEVGVRQAPFPSRASC (PEP number and / or SEQ ID No. 9). [Figure 12] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of RGDSYGEVGVRQAPFPSRASC (PEP number and / or SEQ ID No. 10). [Figure 13] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPSRAS{c-amid-C} (PEP number and / or SEQ ID No. 11). [Figure 14] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPSRAS{c-amid-{dC}} (PEP number and / or SEQ ID No. 12). [Figure 15] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of {dβD}SYGEVGVRQAPFPSRASC (PEP number and / or SEQ ID No. 13). [Figure 16] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of DSYGEVGVRQAPFPSRAS{dC} (PEP number and / or SEQ ID No. 14). [Figure 17] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of {dD}SYGEVGVRQAPFPSRASC (PEP number and / or SEQ ID No. 15). [Figure 18] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-D}SYGEVGVRQAPFPSRAS{c-amid-C} (PEP number and / or SEQ ID No. 16). [Figure 19] An example of the predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{dR}{dA}{dS}{c-amid-{dC}} (PEP number and / or SEQ ID No. 17). [Figure 20] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {dD}SYGEVGVRQAPF{dP}SRASC (PEP number and / or SEQ ID NO: 18). [Figure 21] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {htt-cyclic-D}SYGEVGVRQAPFPSRASC (PEP number and / or SEQ ID NO: 19). [Figure 22] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-peg12-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{dR}{dA}{dS}{c-amid-{dC}}(PEP number and / or SEQ ID NO: 20). [Figure 23] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{r-pal-K}{dA}{dS}{c-amid-{dC}}(PEP number and / or SEQ ID NO: 24). [Figure 24] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-D}SYGEVGVRQAPFPS{r-pal-K}AS{c-amid-C} (PEP number and / or SEQ ID NO: 86). [Figure 25] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{r-ste-K}{dA}{dS}{c-amid-{dC}}(PEP number and / or SEQ ID NO: 87). [Figure 26] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-{dβD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{r-pal-K}{dA}{c-amid-{dS}} (PEP number and / or SEQ ID NO: 157). [Figure 27]Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-D}SYGEVGVRQAPFPSRA{c-amid-S} (PEP number and / or SEQ ID NO: 162). [Figure 28] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-Y}GEVGVRQAPF{c-amid-P} (PEP number and / or SEQ ID NO: 163). [Figure 29] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-Y}GEVGVRQAPFPSRA{c-amid-S} (PEP number and / or SEQ ID NO: 164). [Figure 30] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-D}SYGEVGVRQAPF{c-amid-P} (PEP number and / or SEQ ID NO: 165). [Figure 31] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-Y}GEVGVRQAPFPS{c-amid-R} (PEP number and / or SEQ ID NO: 166). [Figure 32] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-Y}GEVGVRQA{c-amid-P} (PEP number and / or SEQ ID NO: 167). [Figure 33] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-E}VGVRQA{c-amid-P} (PEP number and / or SEQ ID NO: 170). [Figure 34] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-V}GVRQA{c-amid-P} (PEP number and / or SEQ ID NO: 171). [Figure 35] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-Y}GEVGVRQA{c-amid-P} (PEP number and / or SEQ ID NO: 173). [Figure 36] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-Y}GEVGV{hR}QA{c-amid-P} (PEP number and / or SEQ ID NO: 175). [Figure 37] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-{dY}}GEVGV{hR}QA{c-amid-P} (PEP number and / or SEQ ID NO: 177). [Figure 38] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-{dY}}GEVGVRHA{c-amid-P} (PEP number and / or SEQ ID NO: 178). [Figure 39] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-Y}GEVGV{hR}HA{c-amid-P} (PEP number and / or SEQ ID NO: 179). [Figure 40] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-G}LMGVRQA{c-amid-P} (PEP number and / or SEQ ID NO: 182). [Figure 41] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-{dD}}{dS}{dY}GEVGVRQAPF{dP}{dS}{r-pal-K}{c-amid-{dA}}(PEP number and / or SEQ ID NO: 183). [Figure 42] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-acet-Y}GEVGVRQAPFPS{c-amid-{r-pal-K}} (PEP number and / or SEQ ID NO: 185). [Figure 43] Examples of predicted or modeled chemical structures of peptides having the amino acid sequence {n-pal-D}SYGEVGVRQAPFPSRA{c-amid-S} (PEP number and / or SEQ ID NO: 186). [Figure 44]An example of a predicted or modeled chemical structure of a peptide having the amino acid sequence of {n-acet-D}SYGEVGVRQAPFPS{r-pal-K}A{c-amid-S} (PEP number and / or SEQ ID NO: 187).

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Some embodiments of the present invention are described in the "Summary of the Invention", "Brief Description of the Drawings", "Examples", "Claims", and "Drawings" sections of this patent disclosure. This "Brief Description of the Drawings" section provides certain additional embodiments related to the embodiments described throughout this patent disclosure, as well as certain additional explanations and details, and is intended to be read in conjunction with all other sections of this patent disclosure.

[0020] For ease of reference, the Brief Description of the Drawings section is arranged using the following headings and subheadings:

Table 2

[0021] The headings and subheadings used herein are not intended to limit the scope of the present invention in any way. All sections of this patent disclosure should be read in conjunction with all other sections of the patent disclosure. Similarly, those skilled in the art will understand that the various embodiments of the present invention can be combined in various different ways. All such combinations of embodiments are within the scope of the present invention.

[0022] 1. Definitions and Abbreviations To facilitate understanding of this disclosure, certain terms are defined below. Additional definitions will be provided throughout this disclosure in which the terms are used. Unless otherwise defined, or unless a specific meaning is evident from the context of use, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art in which the invention relates. The Dictionary of Cell and Molecular Biology (5th ed. J. M. Cammackie ed., 2013), the Oxford Dictionary of Biochemistry and Molecular Biology (2nd ed. R. Cammack et al. eds., 2008), and The Concise Dictionary of Biomedicine and Molecular Biology (2nd ed. P.S. Juo, 2002) can provide some general definitions of the terms used herein.

[0023] The units, prefixes, and symbols used herein are expressed in the form recognized by the International System of Units (SI). Numerical ranges provided herein include the numerical values ​​that define the ranges.

[0024] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise. The terms “a” (or “an”), as well as “one or more” and “at least one,” are interchangeable.

[0025] As used herein, “and / or” should be understood as a specific disclosure of each of two particular features or components, with or without the other. Thus, the term “and / or” as used in phrases such as “A and / or B” is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Similarly, the term “and / or” as used in phrases such as “A, B, and / or C” is intended to include A, B and C, A, B, or C, A or B, A or C, B or C, A and B, A and C, B and C, A (alone), B (alone), and C (alone).

[0026] Where used herein, the terms “about” and “approximately” mean, when used in relation to numbers, within ±10% of the stated value.

[0027] As used herein, the terms “affinity” and “binding affinity” refer to the combined strength of non-covalent interactions between a binding site on a first molecule (e.g., a peptide described herein) and a second molecule (e.g., a delta-opioid receptor). Unless otherwise indicated herein, “binding affinity” refers to the intrinsic binding affinity that reflects the 1:1 interaction between members of a binding pair (e.g., a peptide and a delta-opioid receptor). The affinity of one molecule to another is expressed by the dissociation constant (K). D Affinity can be expressed by ( ). Affinity can be measured by common methods known in the art (e.g., radiolabeling assays) or as described herein.

[0028] As used herein, the term "agonist" refers to a molecule (e.g., a peptide) that has the ability to produce detectable, measurable, or observable activation of a particular receptor (e.g., a delta-opioid receptor) in, for example, an in vitro or in vivo assay.

[0029] As used herein, the term “amino acid” includes all canonical and non-canonical amino acids known in the art, and includes both natural and unnatural amino acids known in the art. As used herein, the term “naturally occurring” when referring to amino acids means the 20 canonical amino acids encoded by the human gene code (i.e., alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine ​​(Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Val, V)). Examples of non-natural and / or non-canonical amino acids include, but are not limited to, citrulline (Cit), hydroxyproline (Hyp), norleucine (Nle), 3-nitrotyrosine, nitroarginine, ornithine (Orn), naphthylalanine (Nal), Abu, DAB, methionine sulfoxide, or methionine sulfone.

[0030] In some embodiments, the peptides of the present invention may contain one or more “modified amino acids.” As used herein, when used in relation to amino acids, the term “modified” refers to an amino acid that is genetically encoded or chemically different from the form of that amino acid that typically exists in nature. Examples of modified amino acids include, but are not limited to, amino acids having D chirality instead of L chirality, amino acids in beta form instead of alpha form, homoamino acids (e.g., homoalanine), gamma amino acids, beta homoamino acids, N-methyl amino acids, alpha-methyl amino acids, beta-methyl amino acids, fluoro amino acids, acetylated amino acids, acylated amino acids, fatty acid acylated amino acids, amino acid-derived amino acids, methylated amino acids, phosphorylated amino acids, palmitoylated amino acids, glycosylated amino acids, stearic acid-conjugated amino acids, pegylated amino acids, amino acids conjugated to deoxyribonucleic acid or ribonucleic acid or oligonucleotide or polynucleotide, labeled or tagged amino acids (e.g., using fluorescent or isotope labeling or tags), protected amino acids, and amino acids modified using other operations or modifications known in the art.

[0031] Further information regarding “modified amino acids” that may be used in the peptides of the present invention is provided elsewhere in this patent disclosure (see, for example, the description under the subheading “Peptides” for “modified” amino acids). Other modified amino acids, unnatural amino acids, and non-canonical amino acids are known in the art, for example, as described in Sandberg et al., “New Chemical Descriptors Relevant for the Design of Biologically Active Peptides. A Multivariate Characterization of 87 Amino Acids;” J.Med.Chem.;1998;41(14);pp.2481-91).

[0032] Amino acids are typically referred to using either a three-letter or one-letter symbol, as recommended by the IUPAC-IUB Biochemical Nomenclature Committee. Amino acids are referred to herein using those one-letter symbols, as recommended by the IUPAC-IUB Biochemical Nomenclature Committee. Modified amino acids are referred herein using their one-letter symbols in conjunction with one or more prefixes, as further described in the “Modes for Carrying Out the Invention” section of this patent disclosure.

[0033] The terms “comprising,” “consisting of,” and / or “consisting essentially of” are used herein in accordance with their accepted meanings as defined in U.S. Patent Law. Where an embodiment is described using the term “comprising,” other similar embodiments described using the terms “consisting of” and / or “consisting essentially of” are also intended and fall within the scope of the present invention.

[0034] As used herein, the terms “consensus,” “consensus sequence,” or “consensus amino acid sequence” refer to an amino acid sequence obtained by comparing multiple aligned amino acid sequences to identify a shared sequence motif. For example, the present invention provides various consensus amino acid sequences obtained by aligning and comparing the amino acid sequences of peptides having PEP numbers and / or sequences of SEQ ID NOs. 1 to 315, or by comparing subgroups of peptides from among PEP numbers and / or SEQ ID NOs. 1 to 315 and identifying a shared sequence motif. In some cases, a consensus sequence is identified in which the amino acids resulting at each aligned position are identical, in which case the amino acids at each position of the consensus sequence are identified (for example, the consensus amino acid sequences PEP numbers and / or SEQ ID NOs. 747 to 875 provided herein). In some cases, the consensus sequence is identified as having one or more positions that can change in terms of the amino acids that result at those positions, in which case one or more positions within the consensus sequence are identified as variable "X" amino acid residues, and the amino acids that may result at the variable "X" positions are identified (e.g., PEP numbers and / or SEQ ID NOs. 316-437, as provided herein). Amino acid consensus sequences are useful because they provide a way to correlate the structure of a group of proteins or peptides with their biological functions. For example, the consensus amino acid sequences provided herein represent common structural motifs that are thought to correlate with the DOR agonist activity of peptides containing them.

[0035] As used herein, the abbreviation "DOR" refers to the delta opioid receptor. In some embodiments of the present invention, DOR is a mammalian DOR. In some embodiments of the present invention, DOR is a rodent DOR. In some embodiments of the present invention, DOR is a non-human primate DOR. In some embodiments of the present invention, DOR is a human DOR.

[0036] As used herein, the terms “delta opioid agonist” or “DOR agonist” refer to molecules having agonist activity to a delta opioid receptor detectable by any suitable assay for delta opioid receptors known in the art, such as, for example, an effect on cyclic adenosine monophosphate ("cAMP") (e.g., cAMP production) that can be detected using methods known in the art, such as the assay of Example 1; an effect on beta-arrestin (e.g., beta-arrestin recruitment) that can be detected using methods known in the art, such as the assay of Example 4; an effect on calcium (e.g., calcium flux) that can be detected using methods known in the art, such as the assay of Example 2; or an effect on receptor conformational changes and / or receptor internalization that can be detected using methods known in the art, such as the assay of Example 4.

[0037] As used herein, the term “biased DOR agonist” refers to a molecule (such as a peptide) that preferentially activates one or more downstream effects of DOR agonism (as known in the art (e.g., cAMP generation, beta-arrestin recruitment, receptor internalization, calcium flux, and / or others)) compared to one or more other downstream effects of DOR agonism (as measured by a lower EC50 and / or a greater maximal effect).

[0038] Where used herein to refer to peptides, terms such as “stable” or “stable” mean peptides that exhibit less than 10% degradation or less than 10% reduction in biological activity under the described conditions (e.g., in the described composition and / or for the described time and / or at the described temperature), unless a different specific level of stability is described. In some embodiments, the level of stability is evaluated using one or more of the stability assays described in the Examples section of this patent disclosure, including stability assays based on the evaluation of peptide degradation as described by HPLC and stability assays based on the evaluation of biological activity in vivo or in vitro.

[0039] As used herein, and as used in reference to the DOR agonist peptides of the present invention, the term “effective amount” means an amount of DOR agonist peptide sufficient to have the agonist activity of DOR Example 1, or to achieve a detectable, measurable, or observable agonism of DOR, or to achieve a detectable, measurable, or observable biological or therapeutic effect (see the definition of “therapy” as defined below) in the circumstances described. The amount of a given peptide or composition containing such peptide that constitutes an “effective amount” may depend on a variety of factors, including but not limited to the species of subject (e.g., human or some other animal species), the age of the subject, the sex of the subject, the body weight of the subject, the peptide formulation, the route of administration of the peptide, and the planned dosing regimen. The effective amount (which may be a range of effective amounts) can be determined by using standard techniques, e.g., in vitro and / or in vivo assays in the intended subject species or any suitable animal model species. Preferred methods for determining the effective dose include, but are not limited to, dose escalation studies, extrapolation from dose-response curves, and / or extrapolation from other data derived from in vitro and / or in vivo model systems. In some embodiments, the effective dose may be determined on a case-by-case basis according to the judgment of a physician or veterinarian.

[0040] As used herein, the terms “selective agonist of a delta-opioid receptor” or “selective delta-opioid receptor agonist” refer to any compound having a higher binding affinity (or agonist activity) to the delta-opioid receptor than to other opioid receptors (such as the mu-opioid receptor). Preferably, the compound has a binding affinity or agonist activity to the delta-opioid receptor that is at least 2 times, more preferably at least 5 times, more preferably at least 10 times, more preferably at least 20 times, more preferably at least 50 times, more preferably at least 100 times, more preferably at least 200 times, more preferably at least 500 times, more preferably at least 500 times, more preferably at least 500 times, more preferably at least 500 times, or more preferably at least 1000 times higher to the delta-opioid receptor than to other opioid receptors (such as the mu-opioid receptor). Such binding affinity and agonist activity levels can be determined by methods known in the art, including the assay described in Example 3 (for binding activity) or in Example 1, Example 2, or Example 4 (for agonist activity). Similarly, in vivo selectivity for the delta opioid receptor can be determined using any preferred method known in the art, for example, by using gene knockout animals lacking expression of the opioid receptor (e.g., DOR knockout and / or knockout of other opioid receptors (such as the mu-opioid receptor)), or by using an antagonist or competitive agonist having known specificity for a given opioid receptor (such as DOR or the mu-opioid receptor).

[0041] As used herein, the terms “exemplary,” “e.g.,” “for example,” or “such as” mean “example,” “case,” or “such as.” These terms are non-limiting and are not intended to indicate preferred embodiments.

[0042] As used herein, the terms “gastrointestinal site of action” or “GI site of action,” when referring to orally administered DOR agonist peptides described herein, mean that the peptide is primarily active in or near the gastrointestinal (GI) tract, rather than in systemic or other locations in the body (such as the brain) DOR. The GI site of action can be demonstrated using any preferred method known in the art or any method described herein. For example, the GI site of action of the peptides of the present invention is demonstrated when the therapeutic efficacy of the peptide is proportional to the orally administered dose of the peptide, but not proportional to, and independent of, the level of the peptide in the blood circulation after oral administration (i.e., independent of systemic exposure).

[0043] As used herein, the terms “identical” and “percent identity” refer, respectively, to two peptides having the same amino acid sequence and the same amino acid modifications (i.e., they are “identical”) when used to refer to a comparison between two peptides, or to two peptides having a specific percentage of amino acid residues having the same amino acid sequence and the same amino acid modifications (i.e., they have the “percent identity” described) when two peptides are compared and aligned for maximum agreement (introducing gaps or insertions as necessary). For example, if two 10-amino acid peptides have the same amino acid sequence, but one amino acid is acetylated in one peptide or one amino acid has D-chirality instead of L-chirality in the other peptide, then the two peptides are considered 90% identical or have 90% identity. Percent identity can be determined or measured using sequence comparison software or algorithms, or by visual inspection. Various algorithms and software are known in the art that can be used to obtain amino acid sequence alignment and calculate percentage identity.

[0044] As used herein, the term “isolated” refers to a molecule (e.g., a peptide) that is not present in a living object or cell and is typically not found in nature. In some embodiments, the isolated molecule may be purified to such an extent that it is not in a naturally occurring form. In some embodiments, the isolated molecule is “substantially pure.” In some embodiments, the peptides described herein are isolated peptides.

[0045] As used herein, the term “peptide” refers to a polymer of amino acids linked via peptide bonds, whether conformational or internally linked. Thus, the term “peptide” includes linear, branched, disulfide-bridged, and cyclized peptides, as well as peptides having any other topology known in the art. The peptides of the present invention are modified and / or may contain modified amino acids and / or may be interrupted by and / or conjugated with non-amino acids. Peptides may herein be represented using a string of amino acid abbreviations (i.e., an amino acid sequence). Such amino acid sequences may be referred to using a sequence identification number (SEQ ID NO) or a corresponding peptide number (PEP number) according to the sequence listing relating to this application, where the terms SEQ ID NO: 1 and PEP number 1 refer to the same peptide having the same amino acid sequence, the terms SEQ ID NO: 2 and PEP number 2 refer to the same peptide having the same amino acid sequence, and so on for all SEQ ID NOs and PEP numbers. Thus, the two terms may be used interchangeably.

[0046] Unless otherwise specified, peptides represented by their amino acid sequences are presented with the N-terminus on the left, and the sequence is written from the N-terminus to the C-terminus. Peptides may also be represented herein by their chemical structure. Peptides may consist of any number of amino acids, but preferably less than 200 amino acids, such as less than 200, less than 100, less than 50, less than 40, less than 30, less than 20, less than 15, less than 10, 3-20, 4-20, 5-20, 6-20, 7-20, 8-20, 9-20, or 10-20 amino acids.

[0047] As used herein, the term “pharmaceutical composition” means a composition that is in a form that allows for the biological activity of the active ingredient(s) it contains (e.g., peptide(s)) and does not contain any additional ingredients that are unacceptably toxic to the subject to which the composition may be administered. In some embodiments, such compositions may be sterile.

[0048] Where used herein, the term “potency” is used in accordance with its accepted meaning in the art and is a measure of the activity of a given drug (e.g., a peptide described herein) expressed in terms of the amount required to produce the described effect (e.g., detectable activation of DOR). Very potent drugs produce the described effect at low concentrations, while drugs with lower potency produce the described effect only at higher concentrations. The “potency” of peptides described herein may be expressed using any preferred measure known in the art. For example, the potency of peptides may be expressed using their “EC 50 "Value or "IC 50 The value of 'EC' may also be mentioned. For example, in a functional assay, 50 This may be the peptide concentration that induces a biological response that is 50% of the maximum biological response of the peptide in the described functional assay. For example, in the present invention, the EC of the peptide described herein. 50This is the peptide concentration that induces 50% of the maximum DOR agonism of that peptide. EC 50 As an alternative to expressing potency using a value, the potency of the peptides of the present invention may also be described herein in terms of the percentage of DOR agonism observed at a given concentration of the peptide or at a known standard substance (e.g., D-Pen2,5-enkephalin ("DPDPE")) at a given concentration or less. For example, the peptides of the present invention may be described as having at least 50% DOR agonist activity at a concentration of 10 μM or less, or as having at least 90% DOR agonist activity at a concentration of 10 μM or less.

[0049] As used herein, the term “primates” refers to any mammal in the group that includes lemurs, lorises, tarsiers, monkeys, apes, and humans.

[0050] As used herein, the term “retroinverso” refers to a peptide having amino acids in reverse order, in which each amino acid has altered chirality (i.e., L~D or D~L) compared to the described reference amino acid sequence, disregarding the N-terminal and C-terminal modifications of the reference amino acid sequence. The described reference amino acid sequence may be a consensus amino acid sequence in which all amino acid residues can be identified, or in which some of the amino acid residues can be altered in a particular way.

[0051] As used herein, the term “subject” refers to an individual for whom prevention or treatment using the peptides, compositions, or methods described herein is desired, needed, or performed. As used herein, “subject who needs it” is a subject for whom it can be reasonably expected to benefit from prevention or treatment using the peptides, compositions, or methods described herein, as determined, for example, by a medical professional. In some embodiments, the subject is any mammalian subject, including but not limited to humans (male and / or female), non-human primates, dogs, cats, rodents (such as rats, mice, and guinea pigs), cattle, pigs, sheep, goats, horses, and the like, including all mammalian species used in livestock farming, as well as animals kept as pets and in zoos, as well as animals used in preclinical studies. In some embodiments, the subject may be young. In some embodiments, the subject may be adult. In some embodiments, the subject may be elderly adult.

[0052] As used herein, the term “substantially pure” means, when used with respect to peptides, a purity of at least about 70%, preferably at least about 80%, more preferably at least about 90%, and most preferably at least about 95%, 98%, 99%, or 99.9% of the peptide.

[0053] As used herein, the terms “to treat,” “to treat,” and “treatment” mean to achieve and / or perform a method of achieving a detectable, measurable, or observable improvement in one or more clinical parameters or symptoms. For example, in the case of pain, “treatment” means to achieve and / or perform a method of achieving a detectable, measurable, or observable analgesic effect (e.g., including improvement of pain, reduction of pain, elimination of pain, prevention of pain, reduction of pain duration, etc.). Thus, “a method of treating pain” and “a method of inducing analgesia” (and grammatical variations thereof) may be used interchangeably herein.

[0054] The term “means” is used herein in a manner consistent with its use in U.S. patent law and is to be interpreted as broadly as possible in accordance with § 112(f) of the U.S. Patent Act. Accordingly, any claims incorporating the term “means” shall encompass all structures, materials, or actions described herein and all their equivalents. Furthermore, structures, materials, or actions shall include all those described in the Summary of the Invention, Brief Description of the Drawings, Drawings, Modes for Carrying Out the Invention, Examples, Claims, Abstract, and Sequence Listings. The peptides of the present invention are also intended to be referred to as means for achieving the functions or effects described herein. Accordingly, whenever embodiments of the present invention are described without using the term “means,” similar embodiments described as “means” for achieving a particular function or effect should be understood as being contemplated and falling within the scope of the present invention.

[0055] Other terms are defined elsewhere in this patent disclosure or used in accordance with their permissible meanings in the art.

[0056] 2. Peptides This invention provides several novel peptides.

[0057] In some embodiments, the present invention provides peptides comprising a PEP number and / or an amino acid sequence from any one of SEQ ID NOs. 1 to 315 (as described in more detail in Section 2.1 below and elsewhere in this specification). In some embodiments, the present invention provides peptides that can be described using a consensus amino acid sequence from any one of SEQ ID NOs. 316 to 437 (as described in more detail in Section 2.7 below and elsewhere in this specification). In some embodiments, the present invention provides peptides comprising a PEP number and / or an amino acid sequence from any one of SEQ ID NOs. 438 to 752 (as described in more detail in Section 2.8 below and elsewhere in this specification). In some embodiments, the present invention provides peptides comprising a PEP number and / or an amino acid sequence from any one of SEQ ID NOs. 747 to 875 (as described in more detail in Section 2.4 below and elsewhere in this specification). Whenever a peptide is referred herein with respect to its PEP number and / or SEQ ID NO, without further clarification, the peptide has the amino acid residues, amino acid modifications, and other peptide attributes (such as cyclization) specified in the description of its PEP number and / or SEQ ID NO provided herein (e.g., Table 3 below). In some embodiments, the present invention provides peptides having the chemical structures shown in Figures 3 to 44.

[0058] In some embodiments, the present invention provides “variant” peptides comprising peptides that are different from any of the amino acid sequences provided herein, or peptides that are different from any of the amino acid sequences provided herein. Differences between variant peptides and peptides, each including a PEP number and / or SEQ ID NO: can arise at various levels, including the level of amino acid residues (e.g., a variant peptide may include amino acid substitutions, deletions, or additions compared to that of any designated PEP number and / or SEQ ID NO:), the level of amino acid modifications (e.g., a variant peptide may have added or removed modifications compared to that of any designated PEP number and / or SEQ ID NO:, or may include modifications different from those in any designated PEP number and / or SEQ ID NO:), and the level of other peptide attributes (e.g., cyclization, dimerization, polymerization). Examples of such variant peptides are described in more detail in Section 2.9 below and elsewhere in this specification.

[0059] In one embodiment, the peptide of the present invention has a maximum length of 3 amino acids, or 4 amino acids, or 5 amino acids, or 6 amino acids, or 7 amino acids, or 8 amino acids, or 9 amino acids, or 10 amino acids, or 11 amino acids, or 12 amino acids, or 13 amino acids, or 14 amino acids, or 15 amino acids, or 16 amino acids, or 17 amino acids, or 18 amino acids, or 19 amino acids, or 20 amino acids, or 21 amino acids, or 22 amino acids, or 23 amino acids, or 24 amino acids, or 25 amino acids, or 26 amino acids, or 27 amino acids, or 28 amino acids, or 29 amino acids, or 30 amino acids.

[0060] In some embodiments, the peptides of the present invention provide novel tools for studying the role of delta opioid receptors in human pathophysiology.

[0061] In some embodiments, the peptides of the present invention have delta-opioid agonist activity. In some embodiments, the peptides of the present invention have delta-opioid agonist activity in animal models. In some embodiments, the peptides of the present invention have delta-opioid agonist activity in primates. In some embodiments, the peptides of the present invention have delta-opioid agonist activity in non-human primates. In some embodiments, the peptides of the present invention have delta-opioid agonist activity in human subjects.

[0062] In some embodiments, the peptides of the present invention act primarily by delta-opioid receptor agonism rather than mu-opioid receptor agonism. In some embodiments, the peptides of the present invention act primarily by delta-opioid receptor agonism rather than mu-opioid receptor agonism in animal models. In some embodiments, the peptides of the present invention act primarily by delta-opioid receptor agonism rather than mu-opioid receptor agonism in primates. In some embodiments, the peptides of the present invention act primarily by delta-opioid receptor agonism rather than mu-opioid receptor agonism in non-human primates. In some embodiments, the peptides of the present invention act primarily by delta-opioid receptor agonism rather than mu-opioid receptor agonism in human subjects.

[0063] In some embodiments, the peptide of the present invention is a selective delta-opioid receptor agonist. In some embodiments, the peptide of the present invention is a selective delta-opioid receptor agonist in animal models. In some embodiments, the peptide of the present invention is a selective delta-opioid receptor agonist in primates. In some embodiments, the peptide of the present invention is a selective delta-opioid receptor agonist in non-human primates. In some embodiments, the peptide of the present invention is a selective delta-opioid receptor agonist in human subjects.

[0064] In some embodiments, the peptide of the present invention is a specific delta-opioid receptor agonist. In some embodiments, the peptide of the present invention is a specific delta-opioid receptor agonist in animal models. In some embodiments, the peptide of the present invention is a specific delta-opioid receptor agonist in primates. In some embodiments, the peptide of the present invention is a specific delta-opioid receptor agonist in non-human primates. In some embodiments, the peptide of the present invention is a specific delta-opioid receptor agonist in human subjects.

[0065] In some embodiments, the peptides of the present invention exhibit analgesic efficacy in animal models. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in rodent models of pain as described in Example 5. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in primates. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in non-human primates. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in human subjects.

[0066] In some embodiments, the peptides of the present invention exhibit analgesic efficacy in animal models mediated by DOR agonism. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in rodent models mediated by DOR agonism. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in primates mediated by DOR agonism. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in non-human primates mediated by DOR agonism. In some embodiments, the peptides of the present invention exhibit analgesic efficacy in human subjects mediated by DOR agonism. In some embodiments, DOR agonism is determined by the use of gene knockout animals (e.g., DOR knockout) and / or other methods known in the art. In some embodiments, DOR agonism is determined by the use of known DOR-specific antagonists and methods known in the art.

[0067] In some embodiments, the peptides of the present invention exhibit analgesic efficacy in various animal models, such as animal models of acute mechanical pain, acute thermal pain, inflammatory pain, visceral pain, and / or neuropathic pain.

[0068] In some embodiments, the peptides of the present invention exhibit oral efficacy in animal models. In some embodiments, the peptides of the present invention exhibit oral efficacy in primates. In some embodiments, the peptides of the present invention exhibit oral efficacy in non-human primates. In some embodiments, the peptides of the present invention exhibit oral efficacy in human subjects.

[0069] In some embodiments, the peptides of the present invention exhibit oral bioavailability in animal models. In some embodiments, the peptides of the present invention exhibit oral bioavailability in primates. In some embodiments, the peptides of the present invention exhibit oral bioavailability in non-human primates. In some embodiments, the peptides of the present invention exhibit oral bioavailability in human subjects.

[0070] In some embodiments, the peptides of the present invention have sites of action that are not located in the central nervous system. This can be demonstrated by any method known in the art, including the use of conditional knockout, such as that utilizing Cre recombinase, as is known in the art.

[0071] In some embodiments, the peptides of the present invention have a GI action site, which can be demonstrated by any method known in the art, including demonstrating an effect that is proportional to the oral dose but not to systemic exposure (such as analgesic efficacy).

[0072] In some embodiments, the peptides of the present invention provide clinically useful, time-sustaining analgesic efficacy. In some embodiments, the peptides of the present invention provide clinically useful, time-sustaining analgesic efficacy when administered orally. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 2 to 6 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 2 to 12 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 2 to 18 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 2 to 24 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 6 to 12 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 6 to 18 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 6 to 24 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 12 to 18 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 12 to 24 hours. In some embodiments, the peptides of the present invention provide analgesic efficacy that lasts for about 18 to 24 hours.

[0073] In some embodiments, the peptides of the present invention are safe for administration to living subjects. In some embodiments, the peptides of the present invention are safe for administration to primates. In some embodiments, the peptides of the present invention are safe for administration to non-human primates. In some embodiments, the peptides of the present invention are safe for administration to human subjects.

[0074] In some embodiments, the peptides of the present invention do not induce convulsions in living subjects. In some embodiments, the peptides of the present invention do not induce convulsions in primates. In some embodiments, the peptides of the present invention do not induce convulsions in non-human primates. In some embodiments, the peptides of the present invention do not induce convulsions in human subjects.

[0075] In some embodiments, the peptides of the present invention do not cause undesirable neurological effects such as anesthetic effects in living subjects. In some embodiments, the peptides of the present invention do not cause undesirable neurological effects such as anesthetic effects in primates. In some embodiments, the peptides of the present invention do not cause undesirable neurological effects such as anesthetic effects in non-human primates. In some embodiments, the peptides of the present invention do not cause undesirable neurological effects such as anesthetic effects in human subjects.

[0076] In some embodiments, the peptides of the present invention do not induce tolerance after repeated administration in living subjects and / or do not maintain clinical efficacy after repeated administration. In some embodiments, the peptides of the present invention do not induce tolerance after repeated administration in primates and / or do not maintain clinical efficacy after repeated administration. In some embodiments, the peptides of the present invention do not induce tolerance after repeated administration in non-human primates and / or do not maintain clinical efficacy after repeated administration. In some embodiments, the peptides of the present invention do not induce tolerance after repeated administration in human subjects and / or do not maintain clinical efficacy after repeated administration.

[0077] In some embodiments, the peptides of the present invention are not toxic to living subjects. In some embodiments, the peptides of the present invention are not toxic to primates. In some embodiments, the peptides of the present invention are not toxic to non-human primates. In some embodiments, the peptides of the present invention are not toxic to human subjects.

[0078] In some embodiments, the peptides of the present invention are stable as solids (e.g., lyophilized powders) for up to 1 hour at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable as solids (e.g., lyophilized powders) for up to 24 hours at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable as solids (e.g., lyophilized powders) for up to one week at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable as solids (e.g., lyophilized powders) for up to one month at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable as solids (e.g., lyophilized powders) for up to 6 months at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable as solids (e.g., lyophilized powders) as described in Example 7.

[0079] In some embodiments, the peptides of the present invention are stable in an aqueous solution (e.g., in solution with water) for up to 1 hour at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable in an aqueous solution (e.g., in solution with water) for up to 24 hours at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable in aqueous solutions (e.g., solutions with water) for up to one week at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable in aqueous solutions (e.g., solutions containing water) for up to one month at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable in aqueous solutions (e.g., solutions with water) for up to 6 months at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C.

[0080] In some embodiments, the peptides of the present invention are stable in non-aqueous solutions for up to 1 hour at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable in non-aqueous solutions for up to 24 hours at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable in non-aqueous solutions for up to one week at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable in non-aqueous solutions for up to one month at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C. In some embodiments, the peptides of the present invention are stable in non-aqueous solutions for up to 6 months at temperatures below -15°C, or 0 to 4°C, or 4 to 25°C, or 25 to 40°C, or 40 to 70°C, or 70 to 90°C, or 90 to 100°C, or 100 to 110°C, or -20 to 25°C, or -20 to 4°C, or -20 to 40°C.

[0081] In some embodiments, the peptide of the present invention is stable under acidic conditions as described in Example 7. In some embodiments, the peptide of the present invention is stable in the peroxide solution as described in Example 7. In some embodiments, the peptide of the present invention is stable under ultraviolet light as described in Example 7.

[0082] In the embodiments described above, the peptides exhibit less than 10% degradation or less than 10% reduction in biological activity under the conditions described, as described in the Definitions and Abbreviations section of this patent disclosure regarding stability. However, in some embodiments, the peptides of the present invention exhibit a higher level of stability under the above conditions. For example, in some embodiments, the peptides of the present invention exhibit less than 5% degradation or less than 5% reduction in biological activity under the above conditions. In some embodiments, the peptides of the present invention exhibit less than 4% degradation or less than 4% reduction in biological activity under the above conditions. In some embodiments, the peptides of the present invention exhibit less than 3% degradation or less than 3% reduction in biological activity under the above conditions. In some embodiments, the peptides of the present invention exhibit less than 2% degradation or less than 2% reduction in biological activity under the above conditions. In some embodiments, the peptides of the present invention exhibit less than 1% degradation or less than 1% reduction in biological activity under the above conditions.

[0083] Furthermore, in some embodiments, the peptides of the present invention exhibit a lower level of stability under the above conditions. In the above embodiments, the peptides exhibit less than 90% degradation or less than 90% reduction in biological activity under the described conditions. In the above embodiments, the peptides exhibit less than 80% degradation or less than 80% reduction in biological activity under the described conditions. In the above embodiments, the peptides exhibit less than 70% degradation or less than 70% reduction in biological activity under the described conditions. In the above embodiments, the peptides exhibit less than 60% degradation or less than 60% reduction in biological activity under the described conditions. In the above embodiments, the peptides exhibit less than 50% degradation or less than 50% reduction in biological activity under the described conditions. In the above embodiments, the peptides exhibit less than 40% degradation or less than 40% reduction in biological activity under the described conditions. In the above embodiments, the peptides exhibit less than 30% degradation or less than 30% reduction in biological activity under the described conditions. In the above embodiments, the peptides exhibit less than 20% degradation or less than 20% reduction in biological activity under the described conditions.

[0084] In some embodiments, the peptide of the present invention is a biased DOR agonist. In some embodiments, the peptide of the present invention exhibits preferential activation of one effect downstream of DOR activation compared to another effect downstream of DOR activation. In some embodiments, the peptide of the present invention is a biased DOR agonist and has higher potency and / or activity against DOR in the cAMP assay than in the beta-arrestin assay. In some embodiments, the EC50 of the peptide against DOR in the beta-arrestin assay is 1 to 1.2 times, or 1.2 to 1.5 times, or 1.5 to 1.75 times, or 1.75 to 2 times, or 2 to 5 times, or 5 to 10 times, or 10 to 50 times, or 50 to 100 times, or 100 to 10000 times, or 1000 to 10000 times. In some embodiments, the maximum effect of the peptide on DOR in the cAMP assay is 1 to 1.2 times, or 1.2 to 1.5 times, or 1.5 to 1.75 times, or 1.75 to 2 times, or 2 to 5 times, or 5 to 10 times, or 10 to 50 times, or 50 to 100 times, or 100 to 300 times, or 300 to 1000 times, or 1000 to 10000 times, compared to the maximum effect in the beta-arrestin assay.

[0085] In some embodiments, the peptides of the present invention are biased DOR agonists and have higher potency and / or activity in DOR in the calcium flux assay than in the beta-arrestin assay. In some embodiments, the EC50 of the peptide to DOR in the beta-arrestin assay is 1 to 1.2 times, or 1.2 to 1.5 times, or 1.5 to 1.75 times, or 1.75 to 2 times, or 2 to 5 times, or 5 to 10 times, or 10 to 50 times, or 50 to 100 times, or 100 to 300 times, or 300 to 1000 times, or 1000 to 10000 times, compared to the EC50 in the calcium flux assay. In some embodiments, the maximum effect of the peptide on DOR in the calcium flux assay is 1 to 1.2 times, or 1.2 to 1.5 times, or 1.5 to 1.75 times, or 1.75 to 2 times, or 2 to 5 times, or 5 to 10 times, or 10 to 50 times, or 50 to 100 times, or 100 to 300 times, or 300 to 1000 times, or 1000 to 10000 times.

[0086] In some embodiments, the peptides of the present invention are biased DOR agonists and have higher potency and / or activity in DOR in cAMP assays than in receptor internalization assays. In some embodiments, the EC50 of the peptides to DOR in receptor internalization assays is 1 to 1.2 times, or 1.2 to 1.5 times, or 1.5 to 1.75 times, or 1.75 to 2 times, or 2 to 5 times, or 5 to 10 times, or 10 to 50 times, or 50 to 100 times, or 100 to 300 times, or 300 to 1000 times, or 1000 to 10000 times, compared to the EC50 in cAMP assays. In some embodiments, the maximum effect of the peptide on DOR in the receptor cAMP assay is 1 to 1.2 times, or 1.2 to 1.5 times, or 1.5 to 1.75 times, or 1.75 to 2 times, or 2 to 5 times, or 5 to 10 times, or 10 to 50 times, or 50 to 100 times, or 100 to 300 times, or 300 to 1000 times, or 1000 to 10000 times, compared to the maximum effect in the internalization assay.

[0087] In some embodiments, the peptides of the present invention are biased DOR agonists and have higher potency and / or activity in DOR in calcium flux assays than in receptor internalization assays. In some embodiments, the EC50 of the peptide against DOR in a receptor internalization assay is 1 to 1.2 times, or 1.2 to 1.5 times, or 1.5 to 1.75 times, or 1.75 to 2 times, or 2 to 5 times, or 5 to 10 times, or 10 to 50 times, or 50 to 100 times, or 100 to 300 times, or 300 to 1000 times, or 1000 to 10000 times, compared to the EC50 in a calcium flux assay. In some embodiments, the maximum effect of the peptide on DOR in the calcium flux assay is 1 to 1.2 times, or 1.2 to 1.5 times, or 1.5 to 1.75 times, or 1.75 to 2 times, or 2 to 5 times, or 5 to 10 times, or 10 to 50 times, or 50 to 100 times, or 100 to 300 times, or 300 to 1000 times, or 1000 to 10000 times.

[0088] Further details of the peptide of the present invention are provided below.

[0089] 2.1. PEP number and / or sequence number 1-315 Table 3 provides the amino acid sequences of 315 peptides (PEP numbers and / or SEQ ID NOs. 1-315). Each of these peptides was synthesized and demonstrated to possess at least 50% delta opioid receptor agonist activity at ≤100 μM, as described in Example 1. [Table 3] TIFF2026519947000004.tif254162TIFF2026519947000005.tif254157TIFF2026519947000006.tif254155TIFF20265199470 00007.tif254154TIFF2026519947000008.tif254153TIFF2026519947000009.tif254153TIFF2026519947000010.tif244160

[0090] Some peptides, as described in Table 3 and elsewhere in this patent disclosure, include chemical modifications and / or contain “modified” amino acids. In Table 3 and elsewhere in this patent disclosure, amino acids and amino acid modifications are expressed as follows:

[0091] Amino acids are represented using single-letter amino acid codes, often using uppercase letters.

[0092] Amino acids indicated using capital letters without prefixes or surrounding parentheses are naturally occurring amino acids.

[0093] Modified amino acids are indicated by curly braces ("{" and "}"), with the modification(s) of the amino acid residue listed within the braces. For example, {mod-A} or {modA} indicates a modified version of the natural alanine (A) amino acid residue by an exemplary modification (mod or mod-). Specific modifications are represented using prefixes. For example, the amino acid modifications present in the peptides shown in Table 3 are represented using the following prefixes: ● The D-chirality of an amino acid is represented by the prefix "d". For example, {dD} indicates D-aspartic acid. ●Beta-amino acids are represented by the prefix "β," for example, {βD} represents beta-aspartic acid. ● Homoamino acids are represented by the prefix "h," for example, {hD} represents homoaspartic acid. ● Acetylation is represented by the prefix "acet-". ● Amidation is represented by the prefix "amid-". ● Palmitoylation is represented by the prefix "pal-". ● Stearic acid conjugation is represented by the prefix "ste-". Polyethylene glycol (PEG) conjugations are denoted by the prefix "peg-". The number (#) of repeating ethylene glycol units in the conjugated PEG moiety can be denoted using the prefix "peg#-", for example, the prefix "peg12-" represents a polyethylene glycol moiety consisting of 12 ethylene glycol units. The molecular weight of the PEG moiety can also be denoted; for example, the prefix "peg40k-" represents a PEG moiety with a molecular weight of 40 kDa.

[0094] Some of the peptides in Table 3, as described elsewhere in this disclosure, are cyclized. In Table 3 and elsewhere in this disclosure, peptide cyclization is indicated by the prefix "cyclic-". "Head-to-tail" peptide cyclization (i.e., cyclization of the N-terminus to the C-terminus of a peptide) is indicated by the prefix "htt-cyclic-".

[0095] Some of the peptides listed in Table 3 and elsewhere in this patent disclosure include the amino acid surrogate N,N-dimethyltryptamine. In Table 3 and elsewhere in this patent disclosure, the abbreviation "DMT" refers to N,N-dimethyltryptamine.

[0096] Table 3 and other parts of this patent disclosure may also indicate the location of amino acid modifications. For example, modifications to the N-terminus, R-side chain, or C-terminus may be indicated by the prefixes "n-", "r-", or "c-", respectively. For example, N-terminal acetylation may be represented by the prefix "n-acet-", N-terminal palmitoylation by the prefix "n-pal-", side-chain palmitoylation by the prefix "r-pal-" (for example, palmitoylation of the lysine side chain may be represented as {r-pal-K}), and polyethylene glycol (PE The N-terminal conjugation of G) is represented by the prefix "n-peg-" (for example, the N-terminal conjugation of polyethylene glycol to D-cysteine ​​is represented as {n-peg-{dC}}, and the N-terminal conjugation of polyethylene glycol (PEG) moiety having 12 ethylene glycol monomers to D-beta aspartic acid is represented as {n-peg12-{dβD}}, with an average molecular weight of 40 kDa for PEG). The N-terminal conjugation of the moiety is represented as "n-peg40k-", the side-chain conjugation of stearic acid is represented by the prefix "r-ste-" (for example, the conjugation of stearic acid to the lysine side chain is represented as {r-ste-K}), the side-chain conjugation of polyethylene glycol (PEG) is represented by the prefix "r-peg-" (for example, the side-chain conjugation of polyethylene glycol to D-cysteine ​​is represented as {r-peg-{dC}}, the side-chain conjugation of polyethylene glycol (PEG) moiety having 12 ethylene glycol monomers to D-cysteine ​​is represented as {r-peg12-{dC}}, and the side-chain conjugation of PEG moiety with an average molecular weight of 40 kDa is represented as "r-peg40k-"), and the C-terminal amidation is represented by the prefix "c-amid-". In Table 3 and elsewhere in this patent disclosure, any combination of the above prefixes is used as necessary to appropriately represent amino acid modifications or other peptide attributes. For example, the prefix combination {n-acet-{dβD}} represents an N-terminal D-beta-aspartate amino acid residue having an acetyl group attached to a free N-terminal amino group.In Table 3 and elsewhere in this patent disclosure, the conjugation of PEG40k with lysine using the reaction of PEG40k-DBCO with lysine-azide is represented as {{r-peg40k-dbco}-{azide-K}}. In Table 3 and elsewhere in this patent disclosure, the conjugation of PEG40k with cysteine ​​using the reaction of PEG40k-maleimide with cysteine ​​is represented as {r-peg40k-C}. In Table 3 and elsewhere in this patent disclosure, the conjugation of PEG40k with D-cysteine ​​using the reaction of PEG40k-maleimide with cysteine ​​is represented as {r-peg40k-{dC}}.

[0097] In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 1. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 2. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 3. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 4. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 5. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 6. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 7. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 8. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 9. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 10. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 11. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 12. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 13. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 14. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 15. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 16. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 17. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 18. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 19.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 20. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 21. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 22. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 23. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 24. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 25. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 26. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 27. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 28. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 29. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 30. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 31. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 32. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 33. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 34. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 35. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 36. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 37. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 38.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 39. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 40. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 41. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 42. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 43. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 44. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 45. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 46. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 47. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 48. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 49. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 50. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 51. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 52. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 53. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 54. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 55. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 56. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 57.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 58. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 59. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 60. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 61. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 62. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 63. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 64. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 65. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 66. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 67. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 68. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 69. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 70. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 71. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 72. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 73. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 74. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 75. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 76.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 77. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 78. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 79. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 80. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 81. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 82. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 83. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 84. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 85. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 86. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 87. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 88. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 89. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 90. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 91. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 92. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 93. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 94. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 95.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or sequence number 96. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or sequence number 97. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or sequence number 98. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or sequence number 99. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or sequence number 100. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or sequence number. The present invention provides a peptide containing the amino acid sequence of PEP number 101. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 102. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 103. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 104. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 105. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 106. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 107. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 108. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 109. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 110. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or SEQ ID NO: 111. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 112. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 113. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 114. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 115. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 116. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 117. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 118. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 119.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 120. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 121. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 122. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 123. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 124. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 125. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 126. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 127. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 128. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 129. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 130. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 131. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 132. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 133. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 134. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 135. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 136. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 137. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 138.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 139. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 140. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 141. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 142. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 143. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 144. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 145. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 146. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 147. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 148. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 149. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 150. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 151. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 152. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 153. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 154. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 155. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 156. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 157.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 158. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 159. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 160. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 161. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 162. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 163. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 164. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 165. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 166. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 167. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 168. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 169. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 170. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 171. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 172. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 173. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 174. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 175. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 176.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 177. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 178. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 179. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 180. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 181. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 182. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 183. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 184. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 185. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 186. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 187. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 188. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 189. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 190. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 191. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 192. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 193. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 194. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 195.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 196. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 197. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 198. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 199. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 200. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 201. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 202. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 203. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 204. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 205. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 206. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 207. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 208. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 209. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 210. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 211. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 212. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 213. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 214. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 215. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 216. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 217. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 218.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 219. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 220. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 221. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 222. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 223. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 224. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 225. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 226. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 227. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 228. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 229. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 230. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 231. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 232. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 233. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 234. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 235. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 236. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 237.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 238. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 239. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 240. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 241. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 242. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 243. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 244. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 245. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 246. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 247. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 248. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 249. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 250. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 251. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 252. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 253. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 254. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 255. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 256.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 257. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 258. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 259. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 260. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 261. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 262. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 263. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 264. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 265. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 266. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 267. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 268. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 269. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 270. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 271. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 272. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 273. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 274. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 275.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 276. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 277. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 278. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 279. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 280. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 281. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 282. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 283. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 284. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 285. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 286. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 287. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 288. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 289. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 290. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 291. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 292. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 293. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 294.In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 295. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 296. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 297. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 297. The present invention provides a peptide containing the amino acid sequence of sequence number 298. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 299. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 300. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 301. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 302. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 303. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 304. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 305. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 306. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 307. In one embodiment, the present invention provides a peptide containing the amino acid sequence of PEP number and / or sequence number 308. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 309. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 310. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 311. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 312. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 313. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 314. In one embodiment, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 315.

[0098] In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 3. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 4. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 5. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 6. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 7. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 8. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 9. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 10. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 11. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 12. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 13. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 14. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 15. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 16. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 17. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 18. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 19. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 20. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 21. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 22. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 23. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 24. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 25. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 26. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 27.In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 28. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 29. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 30. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 31. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 32. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 33. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 34. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 35. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 36. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 37. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 38. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 39. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 40. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 41. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 42. In one embodiment, the present invention provides a peptide having the chemical structure shown in Figure 43. In another embodiment, the present invention provides a peptide having the chemical structure shown in Figure 44.

[0099] 2.2.Active group In some embodiments, the present invention provides peptides comprising one amino acid sequence from PEP numbers and / or SEQ ID NOs. 1 to 315. Such peptides exhibit at least 50% DOR agonist activity at 100 μM or less, as described in Example 1.

[0100] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 109, 111, 112, 113, 115, 116, 117, 118 ,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149, 150, 152, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 1 84, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 200, 201, 202, 203, 205, 206, 207, 208, 209, 213, 214, 215, 216, 220, 221, 222, 22 3, 224, 228, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 255, 257, 259, 260, 261 ,263,264,265,266,267,268,269,270,271,272,273,275,276,279,280,281,282,283,284,285,286,288,289,290,291,292,293,294,295,296,297,The present invention provides peptides containing any one of the amino acid sequences 298, 299, 300, 301, 302, 303, or 304. Such peptides form a group of peptides ("Group 1"), and together with PEP numbers and / or SEQ ID NOs. 305, 309, 311, 312, 314, and 315, form a group of peptides ("Group 1A"). Both peptides of Group 1 and Group 1A exhibit at least 75% DOR agonist activity at ≤100 μM, as described in Example 1.

[0101] In some embodiments, the present invention relates to PEP numbers and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 74, 75, 76, 77, 7 8, 79, 80, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 103, 104, 105, 106, 107, 109, 112, 113, 115, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 137, 138, 139, 140, 141, 142, 145, 146, 147, 148, 149, 150, 152, 154, 155, 156 ,157,158,159,160,161,162,163,164,165,166,167,168,169,170,172,173,174,175,176,177,178,179,180,181,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,200,201,202,203,208,209,214,215,220,221,222,223,224,231,232,233,234,235,237,2 The present invention provides a peptide containing any one of the following amino acid sequences: 39, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 257, 259, 260, 261, 263, 264, 265, 267, 268, 269, 270, 272, 273, 275, 276, 280, 281, 282, 283, 284, 285, 286, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304.Such peptides form a group of peptides ("Group 2"), and together with PEP numbers and / or SEQ ID NOs. 305, 309, 314, and 315, they form a group of peptides ("Group 2A"). Both peptides of Group 2 and Group 2A exhibit at least 90% DOR agonist activity at ≤100 μM, as described in Example 1.

[0102] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 74, 75, 76 ,77,78,79,80,82,83,85,86,87,88,89,90,91,92,93,95,96,97,99,100,101,103,105,107,109,112,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,137,138,139,140,141,142,145,146,147,148,149,150,152,155,156,157,158,159,160 ,161,162,163,164,165,166,167,168,169,170,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,200,201,202,203,205,206,207,208,209,213,214,215,216,223,224,228,230,231,232,233,234,235,236 The present invention provides a peptide containing any one of the following amino acid sequences: 237, 239, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 255, 257, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 275, 276, 280, 281, 282, 283, 284, 285, 286, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 301, 302, 303, and 304.Such peptides form a group of peptides ("Group 3"), and together with PEP numbers and / or SEQ ID NOs. 305, 309, 311, and 315, they form a group of peptides ("Group 3A"). Both peptides of Group 3 and Group 3A exhibit at least 50% DOR agonist activity at ≤10 μM, as described in Example 1.

[0103] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62, 64, 65, 66, 67 ,68,69,70,71,74,75,78,79,80,82,83,86,87,88,89,90,92,96,97,99,100,105,107,109,112,117,118,119,120,121,122,123,124,125,126,128,129,130,131,134,135,137,138,139,140,145,146,147,148,149,150,155,156,157,158 ,159,160,161,162,163,164,165,166,168,169,170,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,200,201,202,203,205,208,209,214,215,223,224,231,232,233 The present invention provides peptides comprising any one of the amino acid sequences among 234, 235, 237, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 255, 257, 264, 265, 266, 268, 270, 272, 273, 281, 282, 283, 284, 286, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, and 304. Such peptides form a group of peptides ("Group 4"), and together with PEP numbers and / or SEQ ID NOs 305 and 309, form a group of peptides ("Group 4A"). Both peptides from group 4 and group 4A exhibit at least 75% DOR agonist activity at ≤10 μM, as described in Example 1.

[0104] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 45, 46, 52, 53, 54, 55, 56, 57, 5 8, 59, 60, 65, 66, 67, 68, 69, 70, 71, 75, 79, 80, 82, 83, 86, 87, 90, 92, 96, 97, 99, 109, 112, 117, 118, 119, 120, 123, 124, 125, 126, 128, 129, 130, 131, 134, 135, 138, 139, 140, 145, 147, 149, 156, 157, 15 8, 159, 160, 161, 162, 163, 164, 165, 166, 169, 170, 173, 174, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 196, 197, 200, 201, 202, 208, 209, 214, 215, 223, 224, 231, 2 The present invention provides peptides comprising any one of the amino acid sequences 32, 233, 234, 235, 237, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 257, 265, 268, 272, 282, 284, 286, 290, 291, 292, 293, 295, 296, and 297. Such peptides form a group of peptides ("Group 5") and, together with the PEP number and / or SEQ ID NO: 309, form a group of peptides ("Group 5A"). Both peptides of Group 5 and Group 5A exhibit at least 90% DOR agonist activity at 10 μM or less, as described in Example 1.

[0105] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 45, 46, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62 ,65,66,67,68,69,70,71,74,75,79,80,82,83,85,86,87,90,92,96,97,99,105,107,109,112,117,118,119,120,125,126,128,129,130,131,134,138,139,140,147,149,156,157,158,159,160,161,162, 163, 164, 165, 166, 168, 169, 170, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 205, 208, 209, 214, 215, 223, 224, 231, The present invention provides peptides comprising any one of the amino acid sequences 232, 233, 234, 235, 237, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 251, 252, 253, 254, 257, 265, 268, 270, 272, 282, 284, 285, 286, 288, 289, 290, 292, 293, 296, and 297. Such peptides form a group of peptides ("Group 6"), and together with PEP numbers and / or SEQ ID NOs. 305 and 309, they form a group of peptides ("Group 6A"). Both peptides of Group 6 and Group 6A exhibit at least 50% DOR agonist activity at ≤1 μM, as described in Example 1.

[0106] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 22, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 45, 46, 52, 53, 5 4, 55, 56, 57, 58, 59, 60, 65, 66, 67, 68, 69, 70, 71, 75, 79, 82, 83, 86, 87, 90, 92, 96, 99, 109, 117, 118, 119, 125, 126, 129, 130, 131, 139, 140, 147, 149, 156, 157, 158, 159 ,160,161,162,163,164,165,166,169,170,173,174,175,176,177,178,179,180,183,184,185,186,187,188,189,190,191,193,194,200,201,202,205,208,209,2 The present invention provides peptides comprising any one of the amino acid sequences 14, 215, 223, 224, 232, 233, 234, 235, 237, 240, 241, 242, 243, 244, 245, 246, 248, 249, 250, 252, 254, 257, 268, 272, 282, 284, and 290. Such peptides form a group of peptides ("Group 7"), and together with PEP numbers and / or SEQ ID NOs. 305 and 309, form a group of peptides ("Group 7A"). Both peptides of Group 7 and Group 7A exhibit at least 75% DOR agonist activity at ≤1 μM, as described in Example 1.

[0107] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 7, 10, 11, 12, 15, 16, 17, 24, 25, 26, 27, 28, 29, 33, 35, 36, 37, 38, 42, 43, 45, 46, 53, 54, 55, 56, 57, 58, 59, 60, 65, 66, 67, 68, 69, 70, 71, 79, 82, 83, 86, 87, 92, 109, 117, 119, 126, 131, 139, 140, 147, 149, 156, 157, 158, 1 The present invention provides peptides containing any one of the amino acid sequences 59, 160, 161, 162, 163, 169, 170, 173, 174, 176, 178, 180, 183, 184, 185, 186, 187, 188, 189, 191, 193, 194, 200, 201, 202, 208, 209, 214, 215, 232, 233, 234, 235, 241, 242, 243, 244, 245, 246, 248, 249, 250, 252, 272, 282, and 284. Such peptides form a group of peptides ("Group 8"), and together with the PEP number and / or SEQ ID NO: 309, form a group of peptides ("Group 8A"). Both peptides from group 8 and group 8A exhibit at least 90% DOR agonist activity at ≤1 μM, as described in Example 1.

[0108] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs: 16, 17, 24, 86, 87, 157, 162, 163, 164, 165, 166, 167, 170, 171, 173, 175, 177, 178, 179, 182, 183, 185, 186, or 187. Such peptides have been demonstrated to have analgesic effects in vivo, as described in Example 5. Such peptides form a group of peptides ("Group 9").

[0109] 2.3. Modification group In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 1 The present invention provides a peptide containing any one of the following amino acid sequences: 04, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides may consist solely of naturally occurring amino acids and may be produced synthetically or by non-synthetic methods (e.g., by the expression of nucleotide sequences encoding the peptide in a suitable cell type). Such peptides form a group of peptides ("Group 10").

[0110] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 11, 16, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 169, 170, 171, 172, 173, 176, 180, 181, 182, 186, 189, 190, 191, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225 ,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,26 The present invention provides peptides containing any one of the amino acid sequences among 3, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 306, 307, and 308. Such peptides contain only N-terminal or C-terminal modifications and native amino acids and can be produced synthetically or using a combination of non-synthetic methods (e.g., by expression of a nucleotide sequence encoding the peptide in a preferred cell type) and chemical modifications. Such peptides form a group of peptides ("Group 11").

[0111] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 24, 42, 86, 87, 157, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 192, 193, 194, 19 5, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 23 3, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 2 The present invention provides peptides containing any one amino acid sequence from among 71, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, and 315. Such peptides may contain fatty acids and exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 12").

[0112] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 24, 42, 86, 157, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233 ,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,27 The present invention provides peptides containing any one amino acid sequence from among 1, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, and 315. Such peptides contain palmitic acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 13").

[0113] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 186, 188, 189, 191, 193, 194, 195, 196, 197, 198, 199, 200, 201, 2 02, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 27 The present invention provides peptides containing any one of the following amino acid sequences: 3, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, and 315. Such peptides contain an N-terminal palmitic acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 14").

[0114] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs. 24, 42, 86, 157, 183, 184, 185, 187, 188, and 192. Such peptides contain palmitoylated lysine and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 15").

[0115] In some embodiments, the present invention provides peptides comprising a PEP number and / or any one of the amino acid sequences of SEQ ID NOs. 20, 21, 22, and 23. Such peptides contain polyethylene glycol and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 16").

[0116] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 86, 87, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 15 8, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 ,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258, The present invention provides peptides containing any one of the following amino acid sequences: 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, and 315. Such peptides contain non-natural amino acids and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 17").

[0117] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs: 12, 13, 14, 15, 17, 18, 20, 21, 22, 23, 24, 38, 39, 40, 41, 42, 87, 142, 143, 144, 157, 168, 174, 177, 178, 183, 184, 305, 309, 310, 311, 312, 313, 314, 315. Such peptides contain D-amino acids and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 18").

[0118] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs. 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 175, 177, and 179. Such peptides contain homoamino acids and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 19").

[0119] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers 13, 17, 20, 21, 22, 23, 24, 42, 87, 145, 146, 150, 151, 152, 153, 154, 155, 156, 157, and 168. Such peptides contain beta-amino acids and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 20").

[0120] In some embodiments, the present invention provides peptides comprising any one amino acid sequence of PEP number and / or SEQ ID NOs. 150, 151, 152, 153, 154, 155, and 156. Such peptides contain beta-homoamino acids and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 21").

[0121] In some embodiments, the present invention provides peptides comprising PEP numbers and / or amino acid sequences of any one of SEQ ID NOs: 13, 17, 20, 21, 22, 23, 24, 42, 87, 157, and 168. Such peptides contain D-beta-aspartic acid and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 22").

[0122] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs: 16, 17, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 86, 87, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 183, 184, 185, 187, 190. Such peptides have N-terminal acetylation and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 23").

[0123] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 11, 12, 16, 17, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 86, 87, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 17 The present invention provides peptides containing any one amino acid sequence from among 2, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, and 250. Such peptides have C-terminal amidation and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 24").

[0124] In some embodiments, the present invention provides peptides comprising one amino acid sequence of any one of the PEP numbers and / or SEQ ID NO: 19. Such peptides have a cyclic conformation and may exhibit improved properties such as affinity, specificity, and pharmacokinetic properties. Such peptides form a group of peptides ("Group 25").

[0125] 2.4. Sequences In some embodiments, the present invention relates to PEP numbers and / or Sequence IDs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 117, 118 The present invention provides a peptide containing one of the following amino acid sequences: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 149, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 214, 221, 222, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 9-amino acid sequence GEVGVRQAP (PEP number and / or SEQ ID NO: 747). Such peptides form a group of peptides ("Group 26").

[0126] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 115, 116, 117, 118, 119, 12 0, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 148, 149, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165 The present invention provides peptides containing any one of the following amino acid sequences: 166, 167, 168, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 213, 214, 221, 222, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 8-amino acid sequence GEVGVRQA (PEP number and / or SEQ ID NO: 753). Such peptides form a group of peptides ("Group 27").

[0127] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 5 0, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 12 1, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 1 The present invention provides peptides containing any one of the following amino acid sequences: 67, 168, 172, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 7-amino acid sequence GEVGVRQ (PEP number and / or SEQ ID NO: 751). Such peptides form a group of peptides ("Group 28").

[0128] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 1 21, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167 The present invention provides peptides containing any one of the following amino acid sequences: 168, 172, 173, 174, 176, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 6-amino acid sequence GEVGVR (PEP number and / or SEQ ID NO: 752). Such peptides form a group of peptides ("Group 29").

[0129] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 ,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,144,146,147,148,149,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,172, The present invention provides peptides containing any one of the amino acid sequences 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 211, 212, 213, 214, 220, 221, 222, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 5-amino acid sequence GEVGV (PEP number and / or SEQ ID NO: 754). Such peptides form a group of peptides ("Group 30").

[0130] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52 ,53,54,55,56,57,58,59,60,63,64,65,66,67,68,69,70,71,72,73,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, The present invention provides peptides containing any one of the amino acid sequences 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 4-amino acid sequence GEVG (PEP number and / or SEQ ID NO: 755). Such peptides form a group of peptides ("Group 31").

[0131] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54 ,55,56,57,58,59,60,63,64,65,66,67,68,69,70,71,72,73,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 17 The present invention provides peptides containing any one of the following amino acid sequences: 5, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 3-amino acid sequence GEV (PEP number 756). Such peptides form a group of peptides ("Group 32").

[0132] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 117, 118, 119, 120, 121, 1 22, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 149, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 1 The present invention provides peptides containing any one of the following amino acid sequences: 84, 185, 186, 187, 188, 189, 190, 191, 193, 208, 214, 221, 222, 231, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 8-amino acid sequence EVGVRQAP (PEP number and / or SEQ ID NO: 757). Such peptides form a group of peptides ("Group 33").

[0133] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 5 3, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 12 5, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 148, 149, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 173, 174, 180, 183, 184 The present invention provides peptides containing any one of the following amino acid sequences: 185, 186, 187, 188, 189, 190, 191, 193, 200, 208, 213, 214, 221, 222, 230, 231, 233, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 7-amino acid sequence EVGVRQA (PEP number and / or SEQ ID NO: 758). Such peptides form a group of peptides ("Group 34").

[0134] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 180, 183, 184, 185, The present invention provides peptides containing any one of the following amino acid sequences: 186, 187, 188, 189, 190, 191, 193, 200, 201, 208, 212, 213, 214, 220, 221, 222, 229, 230, 231, 233, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 6-amino acid sequence EVGVRQ (PEP number and / or SEQ ID NO: 759). Such peptides form a group of peptides ("Group 35").

[0135] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 5 8, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 1 28, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 176, 178, 180, 183, 184, 185, 186 The present invention provides peptides containing any one of the following amino acid sequences: 187, 188, 189, 190, 191, 193, 200, 201, 202, 208, 212, 213, 214, 220, 221, 222, 229, 230, 231, 233, 235, 251, 253, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 5-amino acid sequence EVGVR (PEP number and / or SEQ ID NO: 760). Such peptides form a group of peptides ("Group 36").

[0136] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 1 32, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 1 The present invention provides peptides containing any one of the following amino acid sequences: 91, 193, 200, 201, 202, 208, 211, 212, 213, 214, 220, 221, 222, 228, 229, 230, 231, 233, 235, 251, 253, 257, 258, 259, 260, 261, 262, 263, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 4-amino acid sequence EVGV (PEP number and / or SEQ ID NO: 761). Such peptides form a group of peptides ("Group 37").

[0137] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 6 5, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 13 6, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 200, 201, 202, 208, 2 The present invention provides peptides containing any one of the following amino acid sequences: 11, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 233, 235, 251, 253, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 3-amino acid sequence EVG (PEP number 762). Such peptides form a group of peptides ("Group 38").

[0138] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 5 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 117, 118, 119, 120, 121, 122, 123 ,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,144,145,149,150,156,157,158,159,160,161,162,163,164,165,166,168,180,183,184,18 The present invention provides peptides containing any one of the following amino acid sequences: 5, 186, 187, 188, 189, 190, 191, 193, 194, 208, 209, 214, 215, 221, 222, 231, 234, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 7-amino acid sequence VGVRQAP (PEP number and / or SEQ ID NO: 748). Such peptides form a group of peptides ("Group 39").

[0139] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 5 7, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 148, 149, 150, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 173, 174, 180, 183, 184, 185, 186, 187, The present invention provides peptides containing any one of the following amino acid sequences: 188, 189, 190, 191, 193, 194, 200, 208, 209, 213, 214, 215, 221, 222, 230, 231, 232, 233, 234, 235, 243, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the six-amino acid sequence VGVRQA (PEP number and / or SEQ ID NO: 763). Such peptides form a group of peptides ("Group 40").

[0140] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 1 32, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 148, 149, 150, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191 The present invention provides peptides containing any one of the following amino acid sequences: 193, 194, 200, 201, 208, 209, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 232, 233, 234, 235, 241, 242, 243, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 5-amino acid sequence VGVRQ (PEP number and / or SEQ ID NO: 764). Such peptides form a group of peptides ("Group 41").

[0141] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134 ,135,136,137,138,139,140,141,142,144,145,146,148,149,150,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,172,173,174,176,178,180,183,184,185,186,187,188,189,190,191,193,194,20 The present invention provides peptides containing any one of the following amino acid sequences: 0, 201, 202, 208, 209, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 232, 233, 234, 235, 240, 241, 242, 243, 248, 249, 250, 251, 253, 254, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 4-amino acid sequence VGVR (PEP number and / or SEQ ID NO: 765). Such peptides form a group of peptides ("Group 42").

[0142] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67 ,68,69,70,71,72,73,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,14 1, 142, 144, 145, 146, 147, 148, 149, 150, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 200, 201, 202, 208, 209, 211, 212, 213, 214 The present invention provides peptides containing any one of the following amino acid sequences: 215, 220, 221, 222, 228, 229, 230, 231, 232, 233, 234, 235, 239, 240, 241, 242, 243, 247, 248, 249, 250, 251, 253, 254, 257, 258, 259, 260, 261, 262, 263, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 306, 307, 308. Such peptides contain the 3-amino acid sequence VGV (PEP number 766). Such peptides form a group of peptides ("Group 43").

[0143] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 5 6, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 149, 150, 151, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 18 The present invention provides peptides containing any one of the following amino acid sequences: 8, 189, 190, 191, 193, 194, 195, 203, 208, 209, 210, 214, 215, 216, 221, 222, 223, 224, 231, 234, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 6-amino acid sequence GVRQAP (PEP number and / or SEQ ID NO: 749). Such peptides form a group of peptides ("Group 44").

[0144] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 ,134,135,136,137,138,139,140,141,142,144,145,148,149,150,151,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,173,174,180,181,182,183,184,185,186,187,188,189,190,191,193, The present invention provides peptides containing any one of the following amino acid sequences: 194, 195, 200, 203, 208, 209, 210, 213, 214, 215, 216, 221, 222, 223, 224, 230, 231, 232, 233, 234, 235, 236, 237, 243, 244, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 5-amino acid sequence GVRQA (PEP number and / or SEQ ID NO: 767). Such peptides form a group of peptides ("Group 45").

[0145] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 6 6, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136 ,137,138,139,140,141,142,144,145,146,148,149,150,151,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,180,181,182,183,184,185,186,187,188,189,190,191,193,194,195,200,20 The present invention provides peptides containing any one of the following amino acid sequences: 1, 203, 208, 209, 210, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 241, 242, 243, 244, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 4-amino acid sequence GVRQ (PEP number and / or SEQ ID NO: 768). Such peptides form a group of peptides ("Group 46").

[0146] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 7 0, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 14 0, 141, 142, 144, 145, 146, 148, 149, 150, 151, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 176, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 193, 194, 195, 200, 201, 202, 203, 204, 208 The present invention provides peptides containing any one of the following amino acid sequences: 209, 210, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 240, 241, 242, 243, 244, 248, 249, 250, 251, 253, 254, 255, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 3-amino acid sequence GVR (PEP number 769). Such peptides form a group of peptides ("Group 47").

[0147] In some embodiments, the present invention relates to PEP numbers and / or Sequence IDs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58 , 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 12 7, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 149, 150, 151, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191 The present invention provides peptides containing any one of the following amino acid sequences: 192, 193, 194, 195, 196, 203, 205, 208, 209, 210, 214, 215, 216, 217, 218, 221, 222, 223, 224, 231, 234, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 5-amino acid sequence VRQAP (PEP number and / or SEQ ID NO: 770). Such peptides form a group of peptides ("Group 48").

[0148] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 6 6, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136 ,137,138,139,140,141,142,144,145,148,149,150,151,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,173,174,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,200,20 The present invention provides peptides containing any one of the following amino acid sequences: 3, 205, 206, 208, 209, 210, 213, 214, 215, 216, 217, 218, 221, 222, 223, 224, 230, 231, 232, 233, 234, 235, 236, 237, 238, 243, 244, 245, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 4-amino acid sequence VRQA (PEP number and / or SEQ ID NO: 750). Such peptides form a group of peptides ("Group 49").

[0149] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 ,70,71,72,73,76,77,78,79,80,81,82,83,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139 ,140,141,142,144,145,146,148,149,150,151,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,200,201,203,205,206, The present invention provides peptides containing any one of the following amino acid sequences: 208, 209, 210, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 241, 242, 243, 244, 245, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the three-amino acid sequence VRQ (PEP number 771). Such peptides form a group of peptides ("Group 50").

[0150] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 13 2, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 149, 150, 151, 152, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 203, 205, 2 The present invention provides peptides containing any one of the following amino acid sequences: 08, 209, 210, 214, 215, 216, 217, 218, 221, 222, 223, 224, 225, 231, 234, 235, 252, 272, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 4-amino acid sequence RQAP (PEP number and / or SEQ ID NO: 772). Such peptides form a group of peptides ("Group 51").

[0151] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 1 42, 143, 144, 145, 148, 149, 150, 151, 152, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 203, 205, 206, 208, 209, 210, 213, 214, 215 The present invention provides peptides containing any one of the following amino acid sequences: 216, 217, 218, 221, 222, 223, 224, 225, 230, 231, 232, 233, 234, 235, 236, 237, 238, 243, 244, 245, 246, 250, 252, 272, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 3-amino acid sequence RQA (PEP number 773). Such peptides form a group of peptides ("Group 52").

[0152] In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 747, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 748, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 749, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 750, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 751, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 752, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 753, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 754, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 755, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 756, wherein the peptide has delta-opioid agonist activity.In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 757, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 758, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 759, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 760, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 761, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 762, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 763, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 764, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 765, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 766, wherein the peptide has delta-opioid agonist activity.In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 767, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 768, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 769, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 770, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 771, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 772, wherein the peptide has delta-opioid agonist activity. In some embodiments, the present invention provides a peptide comprising the amino acid sequence of PEP number and / or SEQ ID NO: 773, wherein the peptide has delta opioid agonist activity.

[0153] 2.5. Sequences containing variants In some embodiments, the present invention relates to PEP numbers and / or SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 5 8, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, The present invention provides peptides containing any one of the following amino acid sequences: 173, 174, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 208, 209, 210, 211, 212, 213, 214, 220, 221, 222, 229, 230, 231, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain variants of amino acid sequences that define group 26, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 53").

[0154] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, The present invention provides peptides containing any one of the following amino acid sequences: 177, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 208, 209, 210, 211, 212, 213, 214, 220, 221, 222, 229, 230, 231, 233, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain amino acid sequence variants that define group 27, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 54").

[0155] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 6 1, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 12 4, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177 The present invention provides peptides containing any one of the following amino acid sequences: 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 201, 208, 209, 210, 211, 212, 213, 214, 220, 221, 222, 229, 230, 231, 233, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain amino acid sequence variants that define group 28, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 55").

[0156] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 6 4, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 1 28, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185 The present invention provides peptides containing any one of the following amino acid sequences: 186, 187, 188, 189, 190, 191, 192, 193, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 233, 235, 251, 253, 254, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain variants of amino acid sequences that define group 29, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 56").

[0157] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 , 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131 ,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,172,173,174,175,176,177,178,179,180,183,184,185,186,187,188,189,190, The present invention provides peptides containing any one of the following amino acid sequences: 191, 192, 193, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 233, 235, 251, 253, 254, 257, 258, 259, 260, 261, 262, 263, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain amino acid sequence variants that define group 30, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("Group 57").

[0158] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 7 0, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 1 37, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 201, 202, 208, 209, 2 The present invention provides a peptide containing any one of the following amino acid sequences: 10, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 233, 235, 251, 253, 254, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304.Such peptides contain amino acid sequence variants that define group 31, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 58").

[0159] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 ,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 1 77, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 21 1, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 239, 240, 241, 242, 243 ,244,247,248,249,250,251,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,291,292,293,294,295,296,The present invention provides peptides containing any one of the amino acid sequences 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 314, and 315. Such peptides contain variants of amino acid sequences that define group 32, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 59").

[0160] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 6 0, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 173, 174, 180, 18 The present invention provides peptides containing any one of the following amino acid sequences: 3, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 208, 209, 210, 211, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 233, 234, 235, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain variants of amino acid sequences that define group 33, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 60").

[0161] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 6 4, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 180, 183, 184, 185, 18 The present invention provides peptides containing any one of the following amino acid sequences: 6, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 208, 209, 210, 211, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 232, 233, 234, 235, 237, 243, 244, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain variants of amino acid sequences that define group 34, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 61").

[0162] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 6 6, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 180, 183, 184, 185, 186, 187, 188, 189, 190, The present invention provides peptides containing any one of the following amino acid sequences: 191, 192, 193, 194, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 215, 220, 221, 222, 229, 230, 231, 232, 233, 234, 235, 237, 241, 242, 243, 244, 249, 250, 251, 253, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain amino acid sequence variants that define group 35, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 62").

[0163] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 7 6, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 1 43, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 215, 219, 2 The present invention provides a peptide containing any one of the following amino acid sequences: 20, 221, 222, 227, 228, 229, 230, 231, 232, 233, 234, 235, 237, 240, 241, 242, 243, 244, 248, 249, 250, 251, 253, 254, 255, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304.Such peptides contain amino acid sequence variants that define group 36, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 63").

[0164] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 7 8, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 1 46, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 17 8, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 215, 219, 220, 221, 222, 227, 228 The present invention provides a peptide containing any one of the following amino acid sequences: 229, 230, 231, 232, 233, 234, 235, 237, 239, 240, 241, 242, 243, 244, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 306, 307, 308.Such peptides contain amino acid sequence variants that define group 37, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 64").

[0165] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 ,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 1 78, 179, 180, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 200, 201, 202, 208, 209, 210, 211, 212, 213, 214, 215, 217, 218, 219, 220, 221, 22 2, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 237, 239, 240, 241, 242, 243, 244, 246, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260 ,261,262,263,264,265,266,267,268,269,270,271,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,The present invention provides peptides containing one of the amino acid sequences 314 or 315. Such peptides contain variants of the amino acid sequence defining group 38, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 65").

[0166] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 6 4, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 173, 174, 180, 181, 183, 184, 185, 186, 187, 188, 189, 19 The present invention provides peptides containing any one amino acid sequence from among 0, 191, 192, 193, 194, 195, 200, 203, 208, 209, 210, 211, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 241, 243, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain amino acid sequence variants that define group 39, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 66").

[0167] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 ,71,72,73,76,77,78,79,80,81,82,83,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,13 8, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 201 The present invention provides a peptide containing any one of the following amino acid sequences: 203, 208, 209, 210, 211, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304.Such peptides contain amino acid sequence variants that define group 40, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 67").

[0168] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 14 0, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 201, 202, 203, 208 The present invention provides a peptide containing any one of the following amino acid sequences: 209, 210, 211, 212, 213, 214, 215, 216, 220, 221, 222, 223, 224, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 253, 254, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304.Such peptides contain amino acid sequence variants that define group 41, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 68").

[0169] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 ,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 1 77, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 201, 202, 203, 204, 208, 209, 210, 211, 212, 213, 214, 21 5, 216, 219, 220, 221, 222, 223, 224, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250 ,251,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,291,292,293,294,295,296,297,298,299,300,301,The present invention provides peptides containing one of the amino acid sequences 302, 303, 304, 306, 307, or 308. Such peptides contain variants of the amino acid sequence defining group 42, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 69").

[0170] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 ,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 1 77, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 200, 201, 202, 203, 204, 208, 209, 210, 211, 212, 213, 214, 21 5, 216, 219, 220, 221, 222, 223, 224, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250 ,251,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,291,292,293,294,295,296,297,298,299,300,301,The present invention provides peptides containing one of the amino acid sequences 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 314, and 315. Such peptides contain variants of the amino acid sequence that define group 43, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 70").

[0171] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 1 33, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195 The present invention provides peptides containing any one of the following amino acid sequences: 196, 200, 203, 205, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 225, 229, 230, 231, 232, 233, 234, 235, 236, 237, 241, 243, 244, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain amino acid sequence variants that define group 44, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid.Such peptides form a group of peptides ("group 71").

[0172] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140 ,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,200,201,203,205,206, The present invention provides a peptide containing any one of the following amino acid sequences: 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 225, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304.Such peptides contain amino acid sequence variants that define group 45, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 72").

[0173] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112 ,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143 ,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,17 4, 175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 201, 202, 203, 204, 205, 206, 208, 209, 21 The present invention provides a peptide containing any one of the following amino acid sequences: 0, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 225, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 253, 254, 255, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304.Such peptides contain amino acid sequence variants that define group 46, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 73").

[0174] In some embodiments, the present invention relates to PEP numbers and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 7 6, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 11 3, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144 ,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 2 10, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 24 1, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 291, 292,The present invention provides peptides containing any one of the amino acid sequences 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 306, 307, and 308. Such peptides contain variants of the amino acid sequence that define group 47, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 74").

[0175] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 1 13, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 14 4, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 174, 180, 18 1, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 203, 205, 206, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218 The present invention provides a peptide containing any one of the following amino acid sequences: 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 241, 243, 244, 245, 249, 250, 252, 272, 273, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304.Such peptides contain amino acid sequence variants that define group 48, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 75").

[0176] In some embodiments, the present invention relates to PEP numbers and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 7 6, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 11 3, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144 ,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 203, 205, 206, 208, 209, 210, 211, 212, 2 13, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 24 6, 247, 248, 249, 250, 252, 272, 273, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300,The present invention provides peptides containing one of the amino acid sequences 301, 302, 303, or 304. Such peptides contain variants of the amino acid sequence that define group 49, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 76").

[0177] In some embodiments, the present invention relates to PEP numbers and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 7 6, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 11 3, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144 ,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175, 176, 177, 178, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 2 10, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 24 3, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288,The present invention provides peptides containing one of the following amino acid sequences: 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain variants of amino acid sequences that define group 50, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 77").

[0178] In some embodiments, the present invention relates to PEP numbers and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 ,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,11 1, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 1 42, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173 ,174,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,200,203,205,206,208,209,210,211,212,213,21 4, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 241, 243, 244, 245, 246, 249, 250, 252, 2 72, 273, 274, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303,The present invention provides peptides containing any one of the 304 amino acid sequences. Such peptides contain variants of the amino acid sequence that define group 51, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 78").

[0179] In some embodiments, the present invention relates to PEP numbers and / or SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 7 6, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 11 3, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144 ,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 200, 201, 203, 205, 206, 208, 209, 210, 2 11, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 24 2, 243, 244, 245, 246, 247, 248, 249, 250, 252, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293,The present invention provides peptides containing one of the amino acid sequences 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 308, and 309. Such peptides contain variants of the amino acid sequence that define group 52, in which one of the amino acids in the sequence is deleted or substituted with a different amino acid. Such peptides form a group of peptides ("group 79").

[0180] 2.6. Additional Sequences In some embodiments, the present invention provides peptides comprising one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 14, 57, 70, 92, 159, and 161. Such peptides contain the 18-amino acid sequence DSYGEVGVRQAPFPSRAS (PEP number and / or SEQ ID NO: 70). Such peptides form a group of peptides ("Group 80").

[0181] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 14, 56, 57, 69, 70, 82, 92, 126, 159, 161. Such peptides contain the 17 amino acid sequence DSYGEVGVRQAPFPSRA (PEP number and / or SEQ ID NO: 126). Such peptides form a group of peptides ("Group 81").

[0182] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 14, 55, 56, 57, 68, 69, 70, 82, 92, 125, 126, 131, 159, 161. Such peptides contain the 16-amino acid sequence DSYGEVGVRQAPFPSR (PEP number and / or SEQ ID NO: 131). Such peptides form a group of peptides ("Group 82").

[0183] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs: 2, 3, 10, 11, 12, 14, 54, 55, 56, 57, 67, 68, 69, 70, 82, 92, 124, 125, 126, 129, 130, 131, 135, 159, 161, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 15-amino acid sequence DSYGEVGVRQAPFPS (PEP number and / or SEQ ID NO: 135). Such peptides form a group of peptides ("Group 83").

[0184] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 53, 54, 55, 56, 57, 66, 67, 68, 69, 70, 80, 82, 83, 92, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 14-amino acid sequence DSYGEVGVRQAPFP (PEP number and / or SEQ ID NO: 138). Such peptides form a group of peptides ("Group 84").

[0185] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NO: 1, 2, 3, 10, 11, 12, 14, 52, 53, 54, 55, 56, 57, 65, 66, 67, 68, 69, 70, 80, 82, 83, 92, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 13-amino acid sequence DSYGEVGVRQAPF (PEP number and / or SEQ ID NO: 137). Such peptides form a group of peptides ("Group 85").

[0186] In some embodiments, the present invention provides a peptide comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 14, 51, 52, 53, 54, 55, 56, 57, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 92, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 149, 156, 159, 161, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 12-amino acid sequence DSYGEVGVRQAP (PEP number and / or SEQ ID NO: 141). Such peptides form a group of peptides ("Group 86").

[0187] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 92, 115, 116, 117, 118, 119, 120, 121, 122, 123 The present invention provides peptides containing any one of the following amino acid sequences: 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 148, 149, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 11-amino acid sequence DSYGEVGVRQA (PEP number and / or SEQ ID NO: 774). Such peptides form a group of peptides ("Group 87").

[0188] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 1 The present invention provides peptides containing any one of the following amino acid sequences: 23, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 148, 149, 154, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 10-amino acid sequence DSYGEVGVRQ (PEP number and / or SEQ ID NO: 775). Such peptides form a group of peptides ("Group 88").

[0189] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 92, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 1 The present invention provides peptides containing any one of the following amino acid sequences: 22, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 148, 149, 153, 154, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 9-amino acid sequence DSYGEVGVR (PEP number and / or SEQ ID NO: 776). Such peptides form a group of peptides ("Group 89").

[0190] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, The present invention provides peptides containing any one of the amino acid sequences among 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 8-amino acid sequence DSYGEVGV (PEP number and / or SEQ ID NO: 777). Such peptides form a group of peptides ("Group 90").

[0191] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 49, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, The present invention provides peptides containing any one of the amino acid sequences among 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 159, 161, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 7-amino acid sequence DSYGEVG (PEP number and / or SEQ ID NO: 778). Such peptides form a group of peptides ("Group 91").

[0192] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 49, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 12 The present invention provides peptides containing any one of the following amino acid sequences: 0, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 159, 161, 192, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 6-amino acid sequence DSYGEV (PEP number and / or SEQ ID NO: 779). Such peptides form a group of peptides ("Group 92").

[0193] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 49, 50, 51, 52, 53, 54, 55, 56, 57, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 1 The present invention provides peptides containing any one of the amino acid sequences among 19, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 151, 152, 153, 154, 155, 156, 159, 161, 192, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 5-amino acid sequence DSYGE (PEP number and / or SEQ ID NO: 780). Such peptides form a group of peptides ("Group 93").

[0194] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 62, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 92, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118 The present invention provides peptides containing any one of the following amino acid sequences: 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 159, 161, 192, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 4-amino acid sequence DSYG (PEP number and / or SEQ ID NO: 781). Such peptides form a group of peptides ("Group 94").

[0195] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 14, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 85, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 12 The present invention provides a peptide containing any one of the following amino acid sequences: 0, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 159, 161, 192, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such a peptide contains the 3-amino acid sequence DSY (PEP number 782). Such peptides form a group of peptides ("group 95").

[0196] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 45, 57, 58, 70, 92, 158, 159, 160, 161. Such peptides contain the 17-amino acid sequence SYGEVGVRQAPFPSRAS (PEP number and / or SEQ ID NO: 783). Such peptides form a group of peptides ("Group 96").

[0197] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 29, 45, 56, 57, 58, 69, 70, 82, 92, 126, 158, 159, 160, 161, 162, 180, 186. Such peptides contain the 16-amino acid sequence SYGEVGVRQAPFPSRA (PEP number and / or SEQ ID NO: 784). Such peptides form a group of peptides ("Group 97").

[0198] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 45, 55, 56, 57, 58, 68, 69, 70, 82, 92, 125, 126, 131, 158, 159, 160, 161, 162, 180, 186. Such peptides contain the 15-amino acid sequence SYGEVGVRQAPFPSR (PEP number and / or SEQ ID NO: 785). Such peptides form a group of peptides ("Group 98").

[0199] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 45, 54, 55, 56, 57, 58, 67, 68, 69, 70, 82, 86, 92, 124, 125, 126, 129, 130, 131, 135, 158, 159, 160, 161, 162, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides include the 14-amino acid sequence SYGEVGVRQAPFPS (PEP number and / or SEQ ID NO: 786). Such peptides form a group of peptides ("group 99").

[0200] In some embodiments, the present invention provides a peptide comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 45, 53, 54, 55, 56, 57, 58, 66, 67, 68, 69, 70, 80, 82, 83, 86, 92, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 158, 159, 160, 161, 162, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides contain the 13-amino acid sequence SYGEVGVRQAPFP (PEP number and / or SEQ ID NO: 787). Such peptides form a group of peptides ("Group 100").

[0201] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 45, 52, 53, 54, 55, 56, 57, 58, 65, 66, 67, 68, 69, 70, 80, 82, 83, 86, 9 The present invention provides peptides containing any one of the following amino acid sequences: 2, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 12-amino acid sequence SYGEVGVRQAPF (PEP number and / or SEQ ID NO: 788). Such peptides form a group of peptides ("Group 101").

[0202] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 45, 51, 52, 53, 54, 55, 56, 57, 58, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 117, 118, 119, 120, 121, 122, 12 The present invention provides peptides containing any one of the following amino acid sequences: 3, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 149, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 214, 221, 222, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 11-amino acid sequence SYGEVGVRQAP (PEP number and / or SEQ ID NO: 789). Such peptides form a group of peptides ("Group 102").

[0203] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 115, 116, 117, 118, 119, 120, 121, 122, 123 The present invention provides peptides containing any one of the following amino acid sequences: 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 148, 149, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 213, 214, 221, 222, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 10-amino acid sequence SYGEVGVRQA (PEP number and / or SEQ ID NO: 790). Such peptides form a group of peptides ("Group 103").

[0204] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 1 The present invention provides a peptide containing any one of the following amino acid sequences: 24, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 148, 149, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such a peptide contains the 9-amino acid sequence SYGEVGVRQ (PEP number and / or SEQ ID NO: 791). Such peptides form a group of peptides ("group 104").

[0205] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, The present invention provides a peptide containing any one of the following amino acid sequences: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 148, 149, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such a peptide contains the 8-amino acid sequence SYGEVGVR (PEP number and / or SEQ ID NO: 792). Such peptides form a group of peptides ("group 105").

[0206] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, The present invention provides a peptide containing any one of the following amino acid sequences: 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 211, 212, 213, 214, 220, 221, 222, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 7-amino acid sequence SYGEVGV (PEP number and / or SEQ ID NO: 793). Such peptides form a group of peptides ("Group 106").

[0207] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 1 The present invention provides a peptide containing any one of the following amino acid sequences: 22, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 6-amino acid sequence SYGEVG (PEP number and / or SEQ ID NO: 794). Such peptides form a group of peptides ("Group 107").

[0208] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 1 23, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180 The present invention provides peptides containing any one of the amino acid sequences among 186, 187, 188, 192, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 5-amino acid sequence SYGEV (PEP number and / or SEQ ID NO: 795). Such peptides form a group of peptides ("Group 108").

[0209] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 ,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,141,143,144,146,147,148,149,151,152,153,154,155,156,158,159,160,161,162,165,180, The present invention provides peptides containing any one of the amino acid sequences 186, 187, 188, 192, 210, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 225, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 4-amino acid sequence SYGE (PEP number and / or SEQ ID NO: 796). Such peptides form a group of peptides ("Group 109").

[0210] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 62 ,63,64,65,66,67,68,69,70,79,80,82,83,84,86,92,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,12 4, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 1 The present invention provides peptides containing any one of the following amino acid sequences: 87, 188, 192, 209, 210, 211, 212, 213, 214, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 3-amino acid sequence SYG (PEP number 797). Such peptides form a group of peptides ("Group 110").

[0211] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 43, 45, 46, 57, 58, 59, 70, 92, 139, 158, 159, 160, 161. Such peptides contain the 16-amino acid sequence YGEVGVRQAPFPSRAS (PEP number and / or SEQ ID NO: 798). Such peptides form a group of peptides ("Group 111").

[0212] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 45, 46, 56, 57, 58, 59, 69, 70, 82, 92, 126, 139, 158, 159, 160, 161, 162, 180, 186. Such peptides contain the 15-amino acid sequence YGEVGVRQAPFPSRA (PEP number and / or SEQ ID NO: 799). Such peptides form a group of peptides ("Group 112").

[0213] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 45, 46, 55, 56, 57, 58, 59, 68, 69, 70, 82, 92, 125, 126, 131, 139, 158, 159, 160, 161, 162, 180, 186. Such peptides contain the 14-amino acid sequence YGEVGVRQAPFPSR (PEP number and / or SEQ ID NO: 800). Such peptides form a group of peptides ("Group 113").

[0214] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NO: 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 45, 46, 54, 55, 56, 57, 58, 59, 67, 68, 69, 70, 82, 86, 92, 124, 125, 126, 129, 130, 131, 135, 139, 158, 159, 160, 161, 162, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, 297. Such peptides include the 13-amino acid sequence YGEVGVRQAPFPS (PEP number and / or SEQ ID NO: 801). Such peptides form a group of peptides ("group 114").

[0215] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 45, 46, 53, 54, 55, 56, 57, 58, 59, 66, 67, 68, 69, 70, 80, 82, 83, The present invention provides peptides containing any one of the following amino acid sequences: 86, 92, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 158, 159, 160, 161, 162, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 12-amino acid sequence YGEVGVRQAPFP (PEP number and / or SEQ ID NO: 802). Such peptides form a group of peptides ("Group 115").

[0216] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 43, 45, 46, 52, 53, 54, 55, 56, 57, 58, 59, 65, 66, 67, 68, 69, 70, 80, 82, 83, 86, 9 The present invention provides peptides containing any one of the following amino acid sequences: 2, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 11-amino acid sequence YGEVGVRQAPF (PEP number and / or SEQ ID NO: 803). Such peptides form a group of peptides ("Group 116").

[0217] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 43, 45, 46, 51, 52, 53, 54, 55, 56, 57, 58, 59, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 117, 118, 119, 120, 121, 122, 1 The present invention provides peptides containing any one of the following amino acid sequences: 23, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 149, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 214, 221, 222, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 10-amino acid sequence YGEVGVRQAP (PEP number and / or SEQ ID NO: 804). Such peptides form a group of peptides ("Group 117").

[0218] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 43, 45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 115, 116, 117, 118, 119, 120, 121, 122, 12 The present invention provides peptides containing any one of the following amino acid sequences: 3, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 148, 149, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 213, 214, 221, 222, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 9-amino acid sequence YGEVGVRQA (PEP number and / or SEQ ID NO: 805). Such peptides form a group of peptides ("Group 118").

[0219] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 32, 33, 34, 38, 39, 40, 41, 43, 45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 1 The present invention provides a peptide containing any one of the following amino acid sequences: 24, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such a peptide contains the 8-amino acid sequence YGEVGVRQ (PEP number and / or SEQ ID NO: 806). Such peptides form a group of peptides ("group 119").

[0220] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 31, 32, 33, 34, 38, 39, 40, 41, 43, 45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 86, 92, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 The present invention provides a peptide containing one of the following amino acid sequences: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 148, 149, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 212, 213, 214, 220, 221, 222, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 7-amino acid sequence YGEVGVR (PEP number and / or SEQ ID NO: 807). Such peptides form a group of peptides ("Group 120").

[0221] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, The present invention provides a peptide containing any one of the following amino acid sequences: 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 146, 147, 148, 149, 153, 154, 155, 156, 158, 159, 160, 161, 162, 165, 180, 186, 187, 188, 211, 212, 213, 214, 220, 221, 222, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 6-amino acid sequence YGEVGV (PEP number and / or SEQ ID NO: 808). Such peptides form a group of peptides ("Group 121").

[0222] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 51, 5 2, 53, 54, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 158, 159, 160, The present invention provides peptides containing any one of the amino acid sequences 161, 162, 165, 180, 186, 187, 188, 211, 212, 213, 214, 219, 220, 221, 222, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 5-amino acid sequence YGEVG (PEP number and / or SEQ ID NO: 809). Such peptides form a group of peptides ("Group 122").

[0223] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 51, 52, 53, 5 4, 55, 56, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 144, 146, 147, 148, 149, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 16 The present invention provides peptides containing any one of the following amino acid sequences: 5, 180, 186, 187, 188, 192, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 4-amino acid sequence YGEV (PEP number and / or SEQ ID NO: 810). Such peptides form a group of peptides ("Group 123").

[0224] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 10, 11, 12, 13, 14, 15, 16, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 51, 52, 53, 54, 55, 56 , 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 79, 80, 82, 83, 84, 86, 92, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 ,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,143,144,146,147,148,149,151,152,153,154,155,156,158,159,160,161,162,165, The present invention provides peptides containing any one of the following amino acid sequences: 180, 186, 187, 188, 192, 210, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 225, 226, 227, 228, 229, 230, 231, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 3-amino acid sequence YGE (PEP number 811). Such peptides form a group of peptides ("Group 124").

[0225] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 57, 58, 59, 60, 70, 85, 88, 89, 90, 91, 92, 139, 158, 159, 160, 161. Such peptides contain the 15-amino acid sequence GEVGVRQAPFPSRAS (PEP number and / or SEQ ID NO: 812). Such peptides form a group of peptides ("Group 125").

[0226] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 56, 57, 58, 59, 60, 69, 70, 82, 85, 88, 89, 90, 91, 92, 126, 139, 158, 159, 160, 161, 162, 164, 180, 186. Such peptides contain the 14-amino acid sequence GEVGVRQAPFPSRA (PEP number and / or SEQ ID NO: 813). Such peptides form a group of peptides ("Group 126").

[0227] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 55, 56, 57, 58, 59, 60, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 125, 126, 131, 139, 158, 159, 160, 161, 162, 164, 180, 186. Such peptides contain the 13-amino acid sequence GEVGVRQAPFPSR (PEP number and / or SEQ ID NO: 814). Such peptides form a group of peptides ("Group 127").

[0228] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 67, 68, 69, 70, 76, 82, 85, 86, 88, The present invention provides peptides containing any one of the following amino acid sequences: 89, 90, 91, 92, 124, 125, 126, 129, 130, 131, 135, 139, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 12-amino acid sequence GEVGVRQAPFPS (PEP number and / or SEQ ID NO: 815). Such peptides form a group of peptides ("Group 128").

[0229] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 53, 54, 55, 56, 57, 58, 59, 60, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82 The present invention provides peptides containing any one of the following amino acid sequences: 83, 85, 86, 88, 89, 90, 91, 92, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 11-amino acid sequence GEVGVRQAPFP (PEP number and / or SEQ ID NO: 816). Such peptides form a group of peptides ("Group 129").

[0230] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 52, 53, 54, 55, 56, 57, 58, 59, 60, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, The present invention provides peptides containing any one of the following amino acid sequences: 86, 87, 88, 89, 90, 91, 92, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 291, 292, 293, 294, 295, 296, and 297. Such peptides contain the 10-amino acid sequence GEVGVRQAPF (PEP number and / or SEQ ID NO: 817). Such peptides form a group of peptides ("Group 130").

[0231] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP numbers and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 57, 58, 59, 60, 61, 70, 85, 88, 89, 90, 91, 92, 93, 94, 95, 139, 158, 159, 160, 161, 208. Such peptides contain the 14-amino acid sequence EVGVRQAPFPSRAS (PEP number and / or SEQ ID NO: 818). Such peptides form a group of peptides ("Group 131").

[0232] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 56, 57, 58, 59, 60, 61, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 126, 139, 158, 159, 160, 161, 162, 164, 180, 186, 208. Such peptides contain the 13-amino acid sequence EVGVRQAPFPSRA (PEP number and / or SEQ ID NO: 819). Such peptides form a group of peptides ("Group 132").

[0233] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NO: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 55, 56, 57, 58, 59, 60, 61, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 125, 126, 131, 139, 158, 159, 160, 161, 162, 164, 180, 186, 208. Such peptides contain the 12-amino acid sequence EVGVRQAPFPSR (PEP number and / or SEQ ID NO: 820). Such peptides form a group of peptides ("Group 133").

[0234] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 93, 94, 9 The present invention provides peptides containing any one of the following amino acid sequences: 5, 124, 125, 126, 129, 130, 131, 135, 139, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 11-amino acid sequence EVGVRQAPFPS (PEP number and / or SEQ ID NO: 821). Such peptides form a group of peptides ("Group 134").

[0235] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 53, 54, 55, 56, 57, 58, 59, 60, 61, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, The present invention provides peptides containing any one of the amino acid sequences 91, 92, 93, 94, 95, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 10-amino acid sequence EVGVRQAPFP (PEP number and / or SEQ ID NO: 822). Such peptides form a group of peptides ("Group 135").

[0236] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 9 The present invention provides a peptide containing any one of the following amino acid sequences: 2, 93, 94, 95, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 208, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 9-amino acid sequence EVGVRQAPF (PEP number and / or SEQ ID NO: 823). Such peptides form a group of peptides ("Group 136").

[0237] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 48, 57, 58, 59, 60, 61, 62, 70, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 139, 142, 145, 150, 158, 159, 160, 161, 208, 209, 215. Such peptides contain the 13-amino acid sequence VGVRQAPFPSRAS (PEP number and / or SEQ ID NO: 824). Such peptides form a group of peptides ("Group 137").

[0238] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 48, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 126, 139, 142, 145, 150, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 215. Such peptides include the 12-amino acid sequence VGVRQAPFPSRA (PEP number and / or SEQ ID NO: 825). Such peptides form a group of peptides ("group 138").

[0239] In some embodiments, the present invention provides a peptide comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 48, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 125, 126, 131, 139, 142, 145, 150, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 215. Such peptides contain the 11-amino acid sequence VGVRQAPFPSR (PEP number and / or SEQ ID NO: 826). Such peptides form a group of peptides ("Group 139").

[0240] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 48, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, The present invention provides peptides containing any one of the following amino acid sequences: 124, 125, 126, 129, 130, 131, 135, 139, 142, 145, 150, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 209, 215, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 10-amino acid sequence VGVRQAPFPS (PEP number and / or SEQ ID NO: 827). Such peptides form a group of peptides ("Group 140").

[0241] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 48, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, 91, 92, 93, 94 The present invention provides peptides containing any one of the following amino acid sequences: 95, 96, 97, 98, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 145, 150, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 209, 215, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 9-amino acid sequence VGVRQAPFP (PEP number and / or SEQ ID NO: 828). Such peptides form a group of peptides ("Group 141").

[0242] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, The present invention provides a peptide containing any one of the following amino acid sequences: 96, 97, 98, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 145, 150, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 183, 184, 185, 186, 187, 188, 189, 208, 209, 215, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 8-amino acid sequence VGVRQAPF (PEP number and / or SEQ ID NO: 829). Such peptides form a group of peptides ("Group 142").

[0243] In some embodiments, the present invention provides peptides comprising any one amino acid sequence from PEP number and / or SEQ ID NO: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 48, 57, 58, 59, 60, 61, 62, 70, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 139, 142, 145, 150, 151, 158, 159, 160, 161, 208, 209, 210, 215, 216, 223, 224. Such peptides include the 12-amino acid sequence GVRQAPFPSRAS (PEP number and / or SEQ ID NO: 830). Such peptides form a group of peptides ("Group 143").

[0244] In some embodiments, the present invention provides a peptide comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 48, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 126, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 223, 224. Such peptides contain the 11-amino acid sequence GVRQAPFPSRA (PEP number and / or SEQ ID NO: 831). Such peptides form a group of peptides ("Group 144").

[0245] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 48, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94 The present invention provides peptides containing any one of the following amino acid sequences: 95, 96, 97, 98, 99, 100, 101, 102, 125, 126, 131, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 223, and 224. Such peptides contain the 10-amino acid sequence GVRQAPFPSR (PEP number and / or SEQ ID NO: 832). Such peptides form a group of peptides ("Group 145").

[0246] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 48, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 124 The present invention provides peptides containing any one of the following amino acid sequences: 125, 126, 129, 130, 131, 135, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 208, 209, 210, 215, 216, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 9-amino acid sequence GVRQAPFPS (PEP number and / or SEQ ID NO: 833). Such peptides form a group of peptides ("Group 146").

[0247] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 48, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, The present invention provides a peptide containing any one of the following amino acid sequences: 101, 102, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 208, 209, 210, 215, 216, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such a peptide contains the 8-amino acid sequence GVRQAPFP (PEP number and / or SEQ ID NO: 834). Such peptides form a group of peptides ("Group 147").

[0248] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 4 6, 47, 48, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 145, 150, 151, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 18 The present invention provides peptides containing any one of the following amino acid sequences: 3, 184, 185, 186, 187, 188, 189, 208, 209, 210, 215, 216, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 7-amino acid sequence GVRQAPF (PEP number and / or SEQ ID NO: 835). Such peptides form a group of peptides ("Group 148").

[0249] In some embodiments, the present invention provides a peptide comprising any one amino acid sequence from PEP number and / or SEQ ID NOs: 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 48, 57, 58, 59, 60, 61, 62, 70, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 139, 142, 145, 150, 151, 158, 159, 160, 161, 208, 209, 210, 215, 216, 217, 218, 223, 224. Such peptides contain the 11-amino acid sequence VRQAPFPSRAS (PEP number and / or SEQ ID NO: 836). Such peptides form a group of peptides ("Group 149").

[0250] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 48, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97 The present invention provides peptides containing any one of the following amino acid sequences: 98, 99, 100, 101, 102, 103, 104, 126, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 217, 218, 223, and 224. Such peptides contain the 10-amino acid sequence VRQAPFPSRA (PEP number and / or SEQ ID NO: 837). Such peptides form a group of peptides ("Group 150").

[0251] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 48, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 9 The present invention provides peptides containing any one of the following amino acid sequences: 7, 98, 99, 100, 101, 102, 103, 104, 125, 126, 131, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 217, 218, 223, and 224. Such peptides contain the 9-amino acid sequence VRQAPFPSR (PEP number and / or SEQ ID NO: 838). Such peptides form a group of peptides ("Group 151").

[0252] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 48, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 124, 1 The present invention provides peptides containing any one of the following amino acid sequences: 25, 126, 129, 130, 131, 135, 139, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 8-amino acid sequence VRQAPFPS (PEP number and / or SEQ ID NO: 839). Such peptides form a group of peptides ("Group 152").

[0253] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 48, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 10 The present invention provides a peptide containing any one of the following amino acid sequences: 3, 104, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 145, 150, 151, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 7-amino acid sequence VRQAPFP (PEP number and / or SEQ ID NO: 840). Such peptides form a group of peptides ("Group 153").

[0254] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 76, 77, 78, 80, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 10 4, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 145, 150, 151, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 1 The present invention provides peptides containing any one of the following amino acid sequences: 85, 186, 187, 188, 189, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 6-amino acid sequence VRQAPF (PEP number and / or SEQ ID NO: 841). Such peptides form a group of peptides ("Group 154").

[0255] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 43, 44, 45, 46, 47, 48, 49, 57, 58, 59, 60, 61, 62, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 9 The present invention provides peptides containing any one of the following amino acid sequences: 9, 100, 101, 102, 103, 104, 105, 106, 107, 139, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 208, 209, 210, 215, 216, 217, 218, 223, 224, and 225. Such peptides contain the 10-amino acid sequence RQAPFPSRAS (PEP number and / or SEQ ID NO: 842). Such peptides form a group of peptides ("Group 155").

[0256] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 43, 44, 45, 46, 47, 48, 49, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 10 The present invention provides peptides containing any one of the following amino acid sequences: 0, 101, 102, 103, 104, 105, 106, 107, 126, 139, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 217, 218, 223, 224, and 225. Such peptides contain the 9-amino acid sequence RQAPFPSRA (PEP number and / or SEQ ID NO: 843). Such peptides form a group of peptides ("Group 156").

[0257] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 1 The present invention provides peptides containing any one of the following amino acid sequences: 00, 101, 102, 103, 104, 105, 106, 107, 125, 126, 131, 139, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 215, 216, 217, 218, 223, 224, and 225. Such peptides contain the 8-amino acid sequence RQAPFPSR (PEP number and / or SEQ ID NO: 844). Such peptides form a group of peptides ("Group 157").

[0258] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 12 The present invention provides a peptide containing any one of the following amino acid sequences: 4, 125, 126, 129, 130, 131, 135, 139, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such a peptide contains the 7-amino acid sequence RQAPFPS (PEP number and / or SEQ ID NO: 845). Such peptides form a group of peptides ("Group 158").

[0259] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 143, 145, 150, 151, 152, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, The present invention provides peptides containing any one of the following amino acid sequences: 188, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 6-amino acid sequence RQAPFP (PEP number and / or SEQ ID NO: 846). Such peptides form a group of peptides ("Group 159").

[0260] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 143, 145, 150, 151, 152, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, The present invention provides peptides containing any one of the following amino acid sequences: 184, 185, 186, 187, 188, 189, 192, 208, 209, 210, 215, 216, 217, 218, 223, 224, 225, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 5-amino acid sequence RQAPF (PEP number and / or SEQ ID NO: 847). Such peptides form a group of peptides ("Group 160").

[0261] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 43, 44, 45, 46, 47, 48, 49, 57, 58, 59, 60, 61, 62, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 10 The present invention provides peptides containing any one of the following amino acid sequences: 1, 102, 103, 104, 105, 106, 107, 108, 139, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, and 226. Such peptides contain the 9-amino acid sequence QAPFPSRAS (PEP number and / or SEQ ID NO: 848). Such peptides form a group of peptides ("Group 161").

[0262] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 43, 44, 45, 46, 47, 48, 49, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 10 The present invention provides peptides containing any one of the following amino acid sequences: 2, 103, 104, 105, 106, 107, 108, 126, 139, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, and 226. Such peptides contain the 8-amino acid sequence QAPFPSRA (PEP number and / or SEQ ID NO: 849). Such peptides form a group of peptides ("Group 162").

[0263] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 30, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 10 The present invention provides peptides containing any one of the following amino acid sequences: 2, 103, 104, 105, 106, 107, 108, 125, 126, 131, 139, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, and 226. Such peptides contain the 7-amino acid sequence QAPFPSR (PEP number and / or SEQ ID NO: 850). Such peptides form a group of peptides ("Group 163").

[0264] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 30, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 124, 12 The present invention provides a peptide containing any one of the following amino acid sequences: 5, 126, 129, 130, 131, 135, 139, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 6-amino acid sequence QAPFPS (PEP number and / or SEQ ID NO: 851). Such peptides form a group of peptides ("Group 164").

[0265] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 143, 145, 147, 150, 151, 152, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, The present invention provides peptides containing any one of the following amino acid sequences: 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 5-amino acid sequence QAPFP (PEP number and / or SEQ ID NO: 852). Such peptides form a group of peptides ("Group 165").

[0266] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 ,52,53,54,55,56,57,58,59,60,61,62,65,66,67,68,69,70,71,72,74,75,76,77,78,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106, 107, 108, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 143, 145, 147, 150, 151, 152, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, The present invention provides peptides containing any one of the following amino acid sequences: 185, 186, 187, 188, 189, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 4-amino acid sequence QAPF (PEP number and / or SEQ ID NO: 853). Such peptides form a group of peptides ("Group 166").

[0267] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66 ,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,13 5, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 147, 149, 150, 151, 152, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 203, 205, 208, 209, 210, 211, 214 The present invention provides peptides containing any one of the following amino acid sequences: 215, 216, 217, 218, 219, 221, 222, 223, 224, 225, 226, 231, 234, 235, 252, 272, 273, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 3-amino acid sequence QAP (PEP number 854). Such peptides form a group of peptides ("Group 167").

[0268] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 31, 43, 44, 45, 46, 47, 48, 49, 57, 58, 59, 60, 61, 62, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 The present invention provides peptides containing any one of the following amino acid sequences: 104, 105, 106, 107, 108, 109, 110, 111, 139, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, and 227. Such peptides contain the 8-amino acid sequence APFPSRAS (PEP number and / or SEQ ID NO: 855). Such peptides form a group of peptides ("Group 168").

[0269] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 31, 43, 44, 45, 46, 47, 48, 49, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 The present invention provides peptides containing any one of the following amino acid sequences: 105, 106, 107, 108, 109, 110, 111, 126, 139, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, and 227. Such peptides contain the 7-amino acid sequence APFPSRA (PEP number and / or SEQ ID NO: 856). Such peptides form a group of peptides ("Group 169").

[0270] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 30, 31, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 10 The present invention provides peptides containing any one of the following amino acid sequences: 4, 105, 106, 107, 108, 109, 110, 111, 125, 126, 131, 139, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, and 227. Such peptides contain the 6-amino acid sequence APFPSR (PEP number and / or SEQ ID NO: 857). Such peptides form a group of peptides ("Group 170").

[0271] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 30, 31, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 124 The present invention provides a peptide containing any one of the following amino acid sequences: 125, 126, 129, 130, 131, 135, 139, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 162, 164, 166, 180, 185, 186, 187, 188, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 5-amino acid sequence APFPS (PEP number and / or SEQ ID NO: 858). Such peptides form a group of peptides ("Group 171").

[0272] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 143, 145, 147, 150, 151, 152, 153, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 18 The present invention provides peptides containing any one of the following amino acid sequences: 8, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 4-amino acid sequence APFP (PEP number and / or SEQ ID NO: 859). Such peptides form a group of peptides ("Group 172").

[0273] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 52 ,53,54,55,56,57,58,59,60,61,62,65,66,67,68,69,70,71,72,74,75,76,77,78,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108, 109, 110, 111, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 137, 138, 139, 140, 142, 143, 145, 147, 150, 151, 152, 153, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 180, 181, 183, 18 The present invention provides peptides containing any one of the following amino acid sequences: 4, 185, 186, 187, 188, 189, 192, 208, 209, 210, 211, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 3-amino acid sequence APF (PEP number 860). Such peptides form a group of peptides ("Group 173").

[0274] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 57, 58, 59, 60, 61, 62, 70, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 The present invention provides peptides containing any one of the following amino acid sequences: 107, 108, 109, 110, 111, 112, 113, 114, 139, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, and 228. Such peptides contain the 7-amino acid sequence PFPSRAS (PEP number and / or SEQ ID NO: 861). Such peptides form a group of peptides ("Group 174").

[0275] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 56, 57, 58, 59, 60, 61, 62, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107 The present invention provides peptides containing any one of the following amino acid sequences: 108, 109, 110, 111, 112, 113, 114, 126, 139, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228. Such peptides contain the 6-amino acid sequence PFPSRA (PEP number and / or SEQ ID NO: 862). Such peptides form a group of peptides ("Group 175").

[0276] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 28, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 55, 56, 57, 58, 59, 60, 61, 62, 68, 69, 70, 82, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107 The present invention provides peptides containing any one of the following amino acid sequences: 108, 109, 110, 111, 112, 113, 114, 125, 126, 131, 139, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 162, 164, 180, 186, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228. Such peptides contain the 5-amino acid sequence PFPSR (PEP number and / or SEQ ID NO: 863). Such peptides form a group of peptides ("Group 176").

[0277] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 28, 29, 30, 31, 32, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 68, 69, 70, 76, 82, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 124 ,125,126,129,130,131,135,139,142,143,145,146,147,150,151,152,153,154,158,159,160,161,162,164,166,180,185,186,187,188,192,208,209,210,21 The present invention provides peptides containing any one of the amino acid sequences 1, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, and 304. Such peptides contain the 4-amino acid sequence PFPS (PEP number and / or SEQ ID NO: 864). Such peptides form a group of peptides ("Group 177").

[0278] In some embodiments, the present invention relates to PEP numbers and / or SEQ ID NOs 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 5 8, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 1 12, 113, 114, 123, 124, 125, 126, 129, 130, 131, 134, 135, 138, 139, 140, 142, 143, 145, 146, 147, 150, 151, 152, 153, 154, 158, 159, 160, 161, 162, 164, 166, 180, 181, 185, 186, 187, 188, 192, 2 The present invention provides peptides containing any one of the following amino acid sequences: 08, 209, 210, 211, 212, 215, 216, 217, 218, 219, 223, 224, 225, 226, 227, 228, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 307, and 308. Such peptides contain the 3-amino acid sequence PFP (PEP number 865). Such peptides form a group of peptides ("Group 178").

[0279] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 57, 58, 59, 60, 61, 62, 63, 70, 101, 84, 85, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 102, 103, 104, 105, 106, 107, 108, The present invention provides peptides containing any one of the following amino acid sequences: 109, 110, 111, 112, 113, 114, 115, 116, 139, 142, 143, 145, 146, 147, 148, 150, 151, 152, 153, 154, 155, 158, 159, 160, 161, 208, 209, 210, 211, 212, 213, 215, 216, 217, 218, 219, 220, 223, 224, 225, 226, 227, and 228. Such peptides contain the six-amino acid sequence FPSRAS (PEP number and / or SEQ ID NO: 866). Such peptides form a group of peptides ("Group 179").

[0280] In some embodiments, the present invention relates to PEP numbers and / or sequence numbers 2, 3, 6, 9, 10, 11, 12, 13, 14, 15, 16, 19, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 50, 56, 57, 58, 59, 60, 61, 62, 63, 69, 82, 84, 85, 70, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, The present invention provides peptides containing any one of the following amino acid sequences: 110, 111, 112, 113, 114, 115, 116, 126, 139, 142, 143, 145, 146, 147, 148, 150, 151, 152, 153, 154, 155, 158, 159, 160, 161, 162, 164, 180, 186, 2...

Claims

1. An isolated delta-opioid receptor agonist peptide, wherein the peptide is (a) Amino acid sequence: X ２ X ３ X ４ X ５ X ６ X ７ X ８ X ９ X １０ X １１ X １２ X １３ X １４ X １５ X １６ X １７ X １８ X １９ being Within the array, independently of each other, X ２ However, it is D, K, or R. X ３ However, it is G, K, S, or W. X ４ However, it is A, D, F, G, K, W, or Y. X ５ However, it is A, C, D, E, G, H, K, N, S, or Y. X ６ However, it is A, D, E, G, I, K, L, Q, or V. X ７ However, it is A, E, G, I, L, M, V, or W. X ８ However, it is A, D, G, S, or V. X ９ However, it is A, C, F, H, I, K, L, P, Q, R, T, V, or W. X １０ However, it is A, C, D, E, G, H, K, P, Q, R, V, W, or Y. X １１ However, it is A, E, H, N, Q, or R. X １２ However, it is A, G, L, P, Q, T, or V. X １３ However, it is A, K, P, or S. X １４ However, it is A, F, I, K, L, or Y. X １５ However, it is K, L, P, or V. X １６ However, it is A, K, L, P, or S. X １７ However, it is A, C, D, H, K, N, Q, R, S, or Y. X １８ However, it is A, G, I, K, or V, and X １９ However, the amino acid sequence is A, D, F, K, or S, or (b) A fragment of the amino acid sequence of part (a), wherein the fragment is 3 to 17 amino acids long, or (c) A retroinversova variant of the amino acid sequence of part (a) or part (b), (d) A variant of the amino acid sequence of part (a), (b), or (c) wherein one or more amino acids are added, deleted, or substituted with different amino acids, or (e) A variant of the amino acid sequence of part (a), (b), (c), or (d), wherein one or more of the amino acids are modified amino acids. An isolated delta-opioid receptor agonist peptide containing [the specified compound].

2. (a) PEP number and / or any one amino acid sequence from sequence numbers 1-315, 438-752, or 747-875, or (b) A fragment of the amino acid sequence of part (a), wherein the fragment is 3 to 17 amino acids long, or (c) A retroinversova variant of the amino acid sequence of part (a) or part (b), (d) A variant of the amino acid sequence of part (a), (b), or (c) wherein one or more amino acids are added, deleted, or substituted with different amino acids, or (e) A variant of the amino acid sequence of part (a), (b), (c), or (d), wherein one or more of the amino acids are modified amino acids. The isolated delta-opioid receptor agonist peptide according to claim 1, comprising:

3. (a) PEP number and / or any one amino acid sequence from SEQ ID NOs. 1 to 315, or (b) A fragment of the amino acid sequence of part (a), wherein the fragment is 3 to 17 amino acids long, or (c) A retroinversova variant of the amino acid sequence of part (a) or part (b), (d) A variant of the amino acid sequence of part (a), (b), or (c) wherein one or more amino acids are added, deleted, or substituted with different amino acids, or (e) A variant of the amino acid sequence of part (a), (b), (c), or (d), wherein one or more of the amino acids are modified amino acids. The isolated delta-opioid receptor agonist peptide according to claim 1, comprising:

4. An isolated delta-opioid receptor agonist peptide containing a PEP number and / or one amino acid sequence from SEQ ID NOs: 1-315, 438-752, or 747-875.

5. An isolated peptide containing one amino acid sequence from PEP number and / or SEQ ID NOs: 1 to 315.

6. An isolated peptide containing any one amino acid sequence from PEP number and / or SEQ ID NOs: 16, 17, 24, 86, 87, 157, 162, 163, 164, 165, 166, 167, 170, 171, 173, 175, 177, 178, 179, 182, 183, 185, 186, or 187.

7. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

16.

8. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

17.

9. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

24.

10. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

86.

11. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

87.

12. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

157.

13. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

162.

14. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

163.

15. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

164.

16. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

165.

17. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

166.

18. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

167.

19. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

170.

20. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

171.

21. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

173.

22. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

175.

23. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

177.

24. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

178.

25. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

179.

26. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

182.

27. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

183.

28. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

185.

29. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

186.

30. An isolated peptide containing the amino acid sequence of PEP number and / or SEQ ID NO:

187.

31. A composition comprising the peptide described in any one of claims 1 to 30.

32. A composition comprising a peptide according to any one of claims 1 to 30, and at least one pharmaceutically acceptable carrier or excipient.

33. A composition comprising a salt of the peptide described in any one of claims 1 to 30.

34. A composition comprising a salt of a peptide according to any one of claims 1 to 30, and at least one pharmaceutically acceptable carrier or excipient.

35. A method for activating a delta-opioid receptor, comprising contacting a delta-opioid receptor, or a cell containing a delta-opioid receptor, with a peptide according to any one of claims 1 to 30, in vitro or in vivo.

36. A method for activating a delta-opioid receptor, comprising contacting a delta-opioid receptor, or a cell containing a delta-opioid receptor, with the composition described in claim 31, in vitro or in vivo.

37. A method for activating a delta-opioid receptor, comprising contacting a delta-opioid receptor, or a cell containing a delta-opioid receptor, with the composition described in claim 32, in vitro or in vivo.

38. A method for activating a delta-opioid receptor, comprising contacting a delta-opioid receptor, or a cell containing a delta-opioid receptor, with the composition described in claim 33, in vitro or in vivo.

39. A method for activating a delta-opioid receptor, comprising contacting a delta-opioid receptor, or a cell containing a delta-opioid receptor, with the composition described in claim 34, in vitro or in vivo.

40. A method for activating a delta opioid receptor in a subject requiring such activation, comprising administering a peptide according to any one of claims 1 to 30 to the subject.

41. A method for activating a delta opioid receptor in a subject requiring such activation, comprising administering the composition according to claim 31 to the subject.

42. A method for activating a delta opioid receptor in a subject requiring such activation, comprising administering the composition according to claim 32 to the subject.

43. A method for activating a delta opioid receptor in a subject requiring such activation, comprising administering the composition according to claim 33 to the subject.

44. A method for activating a delta opioid receptor in a subject requiring such activation, comprising administering the composition according to claim 34 to the subject.

45. A method for treating pain in a subject requiring treatment, comprising administering an effective amount of a peptide according to any one of claims 1 to 30 to the subject.

46. A method for treating pain in a subject requiring treatment, comprising administering an effective amount of the composition according to claim 31 to the subject.

47. A method for treating pain in a subject requiring treatment, comprising administering an effective amount of the composition according to claim 32 to the subject.

48. A method for activating a delta opioid receptor in a subject requiring such activation, comprising administering the composition according to claim 33 to the subject.

49. A method for activating a delta opioid receptor in a subject requiring such activation, comprising administering the composition according to claim 34 to the subject.

50. A composition comprising means for activating a delta-opioid receptor, and a pharmaceutically acceptable carrier or excipient.

51. A composition comprising means for inducing analgesia in a subject, and a pharmaceutically acceptable carrier or excipient.

52. A composition comprising means for activating delta-opioid receptors by oral administration to a subject, and a pharmaceutically acceptable carrier or excipient.

53. A composition comprising means for inducing analgesia by oral administration to a subject, and a pharmaceutically acceptable carrier or excipient.

54. A composition comprising means for activating a delta-opioid receptor having an EC50 of at least 10 micromolars, and a pharmaceutically acceptable carrier or excipient.

55. A composition comprising means for inducing analgesia by activating a delta opioid receptor having an EC50 of at least 10 micromolars, and a pharmaceutically acceptable carrier or excipient.

56. A composition comprising means for selectively activating a delta-opioid receptor in vitro or in vivo, and a pharmaceutically acceptable carrier or excipient.

57. A means for inducing analgesia by selectively activating delta-opioid receptors in vivo, and a composition comprising a pharmaceutically acceptable carrier or excipient.

58. A composition comprising a fatty acid-containing means for activating a delta-opioid receptor, and a pharmaceutically acceptable carrier or excipient.

59. A composition comprising a fatty acid-containing means for inducing analgesia in a subject, and a pharmaceutically acceptable carrier or excipient.

60. A composition comprising a palmitic acid-containing means for activating a delta-opioid receptor, and a pharmaceutically acceptable carrier or excipient.

61. A composition comprising a palmitic acid-containing means for inducing analgesia in a subject, and a pharmaceutically acceptable carrier or excipient.

62. A composition comprising means for activating a delta-opioid receptor in a mammalian subject, and a pharmaceutically acceptable carrier or excipient.

63. A composition comprising means for inducing analgesia in mammalian subjects, and a pharmaceutically acceptable carrier or excipient.

64. A composition comprising means for activating delta-opioid receptors in rodents, and a pharmaceutically acceptable carrier or excipient.

65. A composition comprising means for inducing analgesia in rodents, and a pharmaceutically acceptable carrier or excipient.

66. A composition comprising means for activating delta opioid receptors in non-human primates, and a pharmaceutically acceptable carrier or excipient.

67. A composition comprising means for inducing analgesia in non-human primates, and a pharmaceutically acceptable carrier or excipient.

68. A composition comprising means for activating a delta-opioid receptor in a human subject, and a pharmaceutically acceptable carrier or excipient.

69. A composition comprising means for inducing analgesia in human subjects, and a pharmaceutically acceptable carrier or excipient.

70. A composition comprising means for activating delta-opioid receptors outside the central nervous system (CNS), and a pharmaceutically acceptable carrier or excipient.

71. A means for inducing analgesia by activating delta-opioid receptors outside the central nervous system (CNS), and a composition comprising a pharmaceutically acceptable carrier or excipient.

72. A composition comprising means for safely activating delta opioid receptors in a biological subject, and a pharmaceutically acceptable carrier or excipient.

73. A composition comprising means for safely inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

74. A composition comprising 3-5 aminopeptide means for activating a delta-opioid receptor, and a pharmaceutically acceptable carrier or excipient.

75. A composition comprising 3-5 aminopeptide means for inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

76. A composition comprising 5 to 10 aminopeptide means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

77. A composition comprising 5 to 10 aminopeptide means for inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

78. A composition comprising 10 to 15 aminopeptide means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

79. A composition comprising 10 to 15 aminopeptide means for inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

80. A composition comprising 15 to 20 aminopeptide means for activating a delta opioid receptor, and a pharmaceutically acceptable carrier or excipient.

81. A composition comprising 15 to 20 aminopeptide means for inducing analgesia in a living subject, and a pharmaceutically acceptable carrier or excipient.

82. A method for activating a delta-opioid receptor, comprising contacting a delta-opioid receptor or a cell containing a delta-opioid receptor with the composition described in any one of claims 50 to 81.

83. A method for activating a delta opioid receptor in a biological subject requiring such activation, comprising administering a composition according to any one of claims 50 to 81 to the subject.

84. A method for inducing analgesia in a subject requiring analgesia, comprising administering an effective amount of the composition according to any one of claims 50 to 81 to the subject.

Images